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CHAPTER 1 
INTRODUCTION AND OUTLINE OF INVESTIGATION 
INTRODUCTION 
Cell-mediated immune deficiency in Hodgkin's disease. 
As early as 1902, Dorothy Reed^ made the initial discovery of the 
cellular immune defect in Hodgkin's disease (HD). She had noted the 
absence of cutaneous reactivity to tuberculin. In the last 20 years 
many studies have impugned the Τ cell as the apparent site of this de­
fect, manifested by impaired delayed hypersensitivity^»^ reduced 
responses to Τ cell mitogens^»^»", impaired responses in the allo­
geneic mixed lymphocyte reaction^, and decreased Ε-rosette forma­
tion". These alterations appear to be due to functional abnormalities 
of one or more Τ lymphocyte subpopulations rather than to quantitative 
depletion of Τ lymphocytes. More recent studies have focused on immuno-
regulatory abnormalities mediated through suppressor mechanisms invol­
ving monocytes^ »τ"> τ τ, or suppressor Τ cells''^»'", as well as a 
variety of circulating soluble suppressor factors^»^,16 # However, 
the relationship of these Τ cell abnormalities and suppressor mecha­
nisms to the neoplastic process in Hodgkin's disease remains obscure. 
In fact, it is still uncertain whether immune impairment is a necessary 
prerequisite for establishment of the disease, or a deleterious conse­
quence of the tumor burden of Hodgkin's disease. 
The spleen. 
Beyond its function as a part of the mononuclear phagocyte system 
(MPS), the spleen, as the largest single lymphoid organ of the human 
body, constitutes a major reservoir of mononuclear cells. From studies 
in normal rats^' evidence exists for new cell formation in the red 
pulp and in the perifollicular regions as well as in the germinal cen­
ters. The formation of macrophages, lymphocytes and plasma cells in the 
red pulp and in the perifollicular regions appears to occur especially 
after the injection of heat-damaged red cells^ or antigenic mate­
rial^", whereas the cells in the germinal centers may represent cells 
which provide immunologic memory^O. 
In HD it is still unclear whether Τ lymphocytes in these tissues 
function in the capacity of immunologic surveillance, as a reactive 
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component, or as a neoplastic element. Furthermore, still debate exists 
whether the defects in Τ cell immunity and the peripheral blood lympho­
cytopenia, in patients with Hodgkin's disease, are related to migra­
tion, recruitment, or trapping of Τ lymphocytes in affected tissues, 
since, as far as the spleen is concerned, enhanced numbers of Τ lympho­
cytes have been reported in the spleen of HD patients, whether involve­
ment by the disease does exist or not. 
The importance of the spleen in antibody production has been appre­
ciated for some years. Splenectomy was demonstrated to reduce the abi­
lity of animals and man to produce antibodies and to respond to small 
doses of soluble antigen. Wagener et al.^4 reported a drop in IgM and 
IgG levels in HD patients with stage I and II after splenectomy and a 
drop of IgM in patients with stage III and IV. 
It has been shown in rats that lymphocytes continuously recirculate 
from the blood to the lymphatic sheaths surrounding the splenic arte­
ries and back to the blood via the lymph channels^l. Studies in man 
suggest a similar recirculation of at least a part of the Τ and В 
lymphocyte populations''»". It was demonstrated by Lavender et 
al.2* and Wagstaf et a l . " that peripheral blood lymphocytes accu­
mulate in lymph nodes involved by HD. It has been postulated that early 
in HD, when the spleen is not histologically involved, there is a de­
crease in the number of peripheral blood Τ lymphocytes and an increase 
in Τ cells in the spleen and lymph nodes, as reviewed by Twomey and 
Ricevo. The suggestion that sequestration of functional Τ cells might 
be responsible for the immunological deficit in HD has been put forward 
by De So us a et al. 27,28
 an(j ^ ад ь е е п termed "ecotaxopathy". From 
immunohistochemical studies29»30
 0f tissue sections from spleens 
involved by HD, it was shown that lymphocytes surrounding Reed-Stern-
berg cells are most often Τ cells of the helper phenotype. 
Humoral immunity appears to be unimpaired or rather activated in 
HD31,32,33,34. 
Natural cell-mediated and antibody dependent cellular cytotoxicity. 
Relatively few studies deal with the possible role of natural killer 
(NK) cells in host surveillance during development of Hodgkin's disease 
and their possible contribution to the impairment of immunological 
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functions in this disease. NK cells are lymphocytes with the capacity 
to lyse rapidly, both in vivo and in vitro, tumor cells, virally in-
fected cells, or certain undifferentiated normal cell types. This 
"spontaneous" cytolysis was first recognized as the function of a dis-
crete lymphoid subpopulation in 1975^^»^^. Since that time several 
excellent reviews on this subject have been written^,46,47. Antibody 
dependent cellular cytotoxicity (ADCC) is an immunological defense 
mechanism, in which natural or induced antibodies cooperate with ef-
fector cells. The effector cells of NK and ADCC are thought to be sub-
sets of an Fc-receptor bearing, third population of human mononuclear 
cells, also called "L-cells" or large granular lymphocytes (LGL)^8, a 
subset isolated by Percoli density gradient centrifugation^. 
Since one of the major predictions of the immune surveillance theory 
is that tumor development would be associated with, and in fact preced-
ed by, depressed immunity, more extensive investigations of NK capacity 
and ADCC in Hodgkin's disease appear of interest. 
OUTLINE OF INVESTIGATION 
The initial aim of this study was to investigate antibody-dependent 
and natural cell-mediated cytotoxicity of splenic and peripheral blood 
lymphocytes from patients with Hodgkin's disease (HD). 
For the lymphocyte isolation from human spleen we used counterflow 
centnfugation, which method was adapted to overcome pelleting of cells 
in the separation chamber at the inlet by combining 2 different separa-
tion chambers on line in 1 rotor (chapter 2). 
In chapter 3 the results have been described of the antibody-depen-
dent cellular cytotoxicity of splenic and peripheral blood lymphocytes 
from HD patients and controls, using a DNA flow cytometric assay^O. 
In chapter 4 and 5 the results are given concerning the NK cell acti-
vity of splenic and peripheral blood lymphocytes from HD patients and 
controls, and the in vitro immunomodulatory effects of interleukin-2 
and recombinant human interferons alpha and gamma upon NK cell acti-
vity. 
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Chapter 6 deals with the enuneration of a panel of surface markers, 
tested upon HD splenic cell suspensions. 
An alternative approach of cell function analysis is the study of 
some aspects of cell metabolism. In chapter 7 the results are presented 
of the intracellular activity of 3 key enzymes of the carbohydrate 
metabolism and 2 acid hydrolases. Chapter θ deals with the analysis of 
three purine interconversion enzymes, which are known to be deficient 
in certain immunodeficiency disorders. 
In chapter 9 the results of intracellular nucleotide content measure­
ments are given, analysed in purified splenic lymphocyte suspensions 
from HD patients and controls. 
In chapter 10 some clinical aspects are described in the treatment of 
patients with Hodgkin's disease and other lymphoproliferative disorders 
with recombinant human interferon-alpha 2. 
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CHAPTER 2 
LYMPHOCYTE ISOLATION FROM HUMAN SPLEEN BY COUNTERFLOW CENTRIFUGATION 
EMPLOYING TWO DIFFERENT FLOW CHAMBERS ON LINE 
J.Th.P. Janssen, В.E. de Pauw, J.В.J.M. Smeuldera, J.M.C. Wessels and 
С. Haanen 
Published in: Journal of Immunological Methods 70: 23-30, 1984. 
SUMMARY 
Studies on splenic lymphocytes have hitherto been performed on single 
cell suspensions depleted of phagocytic cells by adherence to plastic 
or incubation with carbonyl iron. These techniques have the disadvanta­
ges of selective cell loss, suboptimal cell purification and cell acti­
vation. This paper describes purification of splenic lymphocytes by the 
use of counterflow centrifugation (CFC). This method was adapted to 
overcome pelleting of cells in the separation chamber to form a plug at 
the inlet and impede adequate flow. By combining 2 different separation 
chambers on line in 1 rotor this problem was overcome. Of all lympho­
cytes recovered after CFC 88.θ ± 1Λ% were collected in 2 pooled frac­
tions with a purity of > 9B% and a cell viability of 95%. After CFC, 
80.8 ± 12.ISS of the viable cells loaded were recovered. 
INTRODUCTION 
Methods currently in use for isolation of cells from human spleen in­
clude isopycnic^»2 or isokinetic·'»^ gradients. Depletion^»^
 o r 
enrichment^»8 of splenic macrophages is attained by means of carbonyl 
iron ingestion or adherence to plastic. Although these techniques are 
widely accepted, there are disadvantages inherent in each, such as se­
lective cell loss, release phenomena and cell activation. 
An alternative method for cell fractionation is counterflow centrifu-
gation (CFC, elutriation). This has proved to be an excellent method 
for the separation of lymphocytes and monocytes from peripheral 
blood',10,11,12,13,14. 
This paper describes the use of a modified and improved CFC technique 
making use of 2 different flow chambers connected on line, which per­
mits the isolation of highly purified intact lymphocytes from human 
splenic tissue. 
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MATERIALS AND METHODS 
Spleens. 
Spleens used in this study were obtained from 6 patients with Hodg-
kin's disease and 1 patient with non-Hodgkin lymphoma, who underwent 
staging laparotomy. Two normal spleens were obtained from patients with 
accidental splenic rupture. The spleens from the lymphoma patients were 
histologically not involved by the disease. 
Preparation of single cell suspensions. 
Tissue specimens of about 10 g were taken and cut into small pieces. 
The tissue fragments were gently pressed through a 75 μπι nylon filter 
with continuous addition of Tris-buffered Minimum Essential Medium 
(MEM, pH 7.35), supplemented with 0.05 mg/ml DNase (deoxyribonuclease 
I, grade II from bovine pancreas; Boehringer) to prevent cell clumping 
and 5% (v/v) heat-inactivated pooled human serum. After incubation for 
30 min at 37° С the cell suspension was passed through a 40 μπι nylon 
filter. Thirty milliliters of the cell suspension (107 cells/ml) were 
layered on a discontinuous Percoli dual density gradient (specific gra­
vities respectively 1.045 and 1.077 g/ml at 20oC, pH 7.35, ionic 
strength 295 mosmol/kg) and spun at 800 χ g for 15 min at ZCPC. Dead 
cells and cell fragments, collecting at the 1.045 interphase, were re­
moved. Intact cells were recovered from the 1.077 interphase and washed 
once in Ca2+/Mg2+-free glucose phosphate-buffered saline, supple­
mented with 100 mg dipotassium-EDTA and 4 g bovine serum albumin/1 
(glucose-PBS-BSA). After centrifugation at 600 χ g for 10 min at 20oC 
the cells were resuspended in the same buffer at a concentration of 5 χ 
107/ml. 
Counterflow centrifugation. 
Cell separation was performed in a J 2-21 С Beekman centrifuge 
equipped with the JE-6 elutriation rotor. A combination of the standard 
Beekman and the Sanderson separation chambers (Beekman Instruments, 
Palo Alto, CA, USA) was used on line in 1 rotor. 
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Prior to introduction of the cell sample, the rotor speed was adjust­
ed to 2650 rpm and the counterflow established at 12 ml/min. During 
CFC, the temperature of the centrifuge and the elutriation medium were 
maintained at 2CPC. By means of an infusor, 5 ml of the cell suspension 
(5 χ 10? cells/ml) were introduced. The gradual diminution of centri­
fugal speed at a constant rate of 12 ml/min glucose-PBS-BSA permitted 
cells to emerge from the separation chambers. Optimal separation for 
each cell size fraction was established by means of cell scatter ana­
lysis of the effluent which provided continuous monitoring of cell size 
and number''. 
Cell counting and characterization. 
Cell numbers in the starting material, in the suspension obtained af­
ter density centrifugation, and in the elutriated fractions were 
measured with a Coulter Counter (model ZF). Cytocentrifuge preparations 
were made according to Talstad and Gundersen^ and stained with May-
Grünwald-Giemsa and for non-specific esterase''б. Differential count­
ing of 400 cells was performed by 2 investigators. 
Cell viability. 
Cell viability was assessed by ethidiun bromide (EB) exclusion com­
bined with fluorescein diacetate (FDA). Twenty microliters FDA (5 mg/ml 
acetone) were added to 5 ml Hank's buffered balanced salt solution 
(HBBS). Cells were suspended in 1 ml of this FDA solution at a concen­
tration of 1 χ lOfyml and incubated for 15 min at ЗТ'-'С. After addi­
tion of 50 μΐ ЕВ (0.025 mg ЕВ, 5.84 mg NaCl and 12.1 mg Tris/ml, pH 
7.5) green and red fluorescence were measured with a flow cytometer 
(Orthophysics 50-H, Westwood, MA, USA). Viable eels were FDA-positive 
(green cytoplasmic fluorescence^) and dead cells EB-positive (red 
DNA-fluorescence^), for each determination 2-4 χ Ю 4 cells were 
counted. 
RESULTS 
Initially the standard Beekman and Sanderson chambers were used sepa­
rately for counterflow centrifugation of spleen cells. 
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With the Beekman chamber, frequently pelleting of cells occurred du­
ring loading at a constant counterflow rate of 12 ml/min and a rotor 
speed of 2650 rpm. A cell plug was formed at the inflow side of the 
chamber, and impeded adequate flow. Variation of rotor speed and coun­
terflow rate did not alleviate this problem. 
When the Sanderson chamber was used under the same conditions no pel­
leting was noted. However, more than 25% of the cells left the rotor 
during introduction of the cell sample. In order to prevent elution of 
these cells during loading, rotor speed had to be increased to 2Θ70 
rpm. At this higher rotor speed the larger cells were more concentrated 
near the apex. This repeatedly caused pelleting of cells in the Sander­
son chamber аз well. 
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Fig. 1. The upper panel shows the percentage of spleen cells in the 
different elutriation fractions at various centrifuqation speeds with 
the Sanderson chamber. In the lower panel the same data are given for 
the Beekman separation chamber. Medi ил flow rate was kept constant 
during both elutriations at 12 ml/min. 
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The separation characteristics of the 2 chambers, which are shown in 
Fig. 1, turned out to be different: the cells were eluted from the 
Beekman chamber at lower rotor speeds in comparison with the Sanderson 
chamber. 
In view of these different separation characteristics the combination 
of both chambers on line in 1 rotor proved to be beneficial in prevent­
ing pelleting of cells. The Sanderson chamber was placed in the origi­
nal operating position, while the Beekman chamber was placed at the 
site of the bypass. During loading at a rotor speed of 2650 rpm and a 
constant counterflow of 12 ml/min the small lymphocytes left the San­
derson chamber and were collected in the Beekman chamber. Prior to elu­
triation a scatter profile of the total cell population was made (Fig. 
2, upper profile). 
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Fig. 2. The upper profile represents the scatter histogram of the cells 
prior to elutriation. The lower profiles correspond with the scatter 
histograms of fractions 1, 2, 3, 4 and 5 during elutriation. 
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Table 1 . P u r i t y , y i e l d and v i a b i l i t y o f the d i f f e r e n t f r a c t i o n s 3 . 
Starting material 
Lhfractionated material 
(af ter density 
centrifugation) 
E l u t r i a t i m fract ion 
1 
2 
3 
4 
5 
6 
ffey-Grürwald-Giensa 
S l y 
70.6 ± 12.9 
81.0 ±10.5 
>99 
>99 
96.2 ± 1.6 
41.3 ± 6.8 
11.5 ± 5 . 0 
29.6 + 9.6 
%gc 
19.9 ±11.5 
11.4 + 9.3 
-
-
< 1 
14.0 ± 9.4 
73.1 ± 13.7 
47.6 ± 8 . 8 
% np 
9.5 ± 
7.5 + 
-
< 1 
3.2 ± 
44.6 ± 
16.2 + 
22.6 ± 
3.1 
3.0 
1.4 
3.6 
8.1 
10.0 
Esteraseb 
ft) 
10.0 + 2.1 
8.3 ± 2.8 
-
< 1 
3.5 ± 1.0 
45.7 ± 3.5 
15.2 ± 7.7 
24.7 ± 10.1 
іеІсЯ 
% l y 
3.5 ± 0.6 
72.1 + 2.8 
16.7 + 3.2 
4.2 + 2.3 
1.7 ± 1.2 
0.9 ± 0.8 
% gr 
-
-
< 1 
11.9 ± 9.4 
75.0 ± 17.8 
12.9 ± 12.0 
%np 
-
-
6.4 ± 3.0 
55.9 ± 9.4 
27.9 ± 15.2 
9.5 ± 11.5 
V i i > i l i t y 
№) 
78.9 ± 10.8 
87.9 ± 10.2 
92.6 ± 3.9 
95.4 ± 1.5 
96.0 ± 1.2 
94.6 ± 1.9 
86.8 ± 5.2 
42.2 ± 10.1 
4tesults are expressed as mean % ± SD. 
^Esterase positive c e l l s . 
cExpressed as the relat ive d ist r ibut ion of lytrphocytes ( l y ) , grai i locytes (gr) and macrophages (mp) in the di f ferent fract ions. 
During loading a small nunber of cells together with erythrocytes and 
thrombocytes left the rotor and were collected in fraction 1, After the 
loading rotor speed was decreased to a value where cells with a scatter 
signal similar to the top of the original scatter profile left the 
rotor, fraction 2 was collected. When the nunber of cells leaving the 
separation chamber fell below 200 cells/s, the rotor speed was again 
decreased stepwise and fraction 3 was gathered. This stepwise decrease 
in rotor speed was continued until cells with a distinct scatter signal 
(mainly macrophages) left the elutriator, at which point the rotor 
speed was increased by 15 rpm in order to elute as many as possible of 
the remaining lymphocytes. In this way a minimum admixture of macro­
phages was obtained. 
At the point where less than 100 cells/s left the rotor, speed was 
again decreased stepwise for as long as a double peaked scatter signal 
was visible; this constituted fraction 4. Finally the rotor was stopped 
and the cells eluted corresponded to fraction 5. Thereafter, medium 
flow rate was increased to 30 ml/min and a final fraction (fraction 6) 
was collected. Cells in the different fractions were then concentrated 
by centrifugation (600 χ g,10 min, 2(fC) and further analyses were per­
formed. 
Overall cell recovery after 2-chamber elutriation of 9 separate 
spleen cell suspensions was 71.7 ± 15.IS. When corrected for non-viable 
cells in the unfractionated material (viability 87.9 ± 10.2%), total 
cell recovery was 80.θ ± 12.1%. In table 1 the composition and viabi­
lity of cells in the starting material, the unfractionated cell sus­
pension and elutriation fractions are shown. Fraction 1 was collected 
during loading and contained thrombocytes and erythrocytes together 
with a small percentage of small lymphocytes. Fraction 2 consisted of 
the majority of the lymphocytes (72.1 ± 2.8% of all lymphocytes re­
covered) with high purity (> 99%). Fraction 3 contained 16.7 ± 3.2SÓ of 
the lymphocytes with a purity of 96.2 ± 1.6% and a slight admixture of 
macrophages (3.2 ± 1.4л) representing 6.5 ± 3.1% of all macrophages 
elutriated. Fraction 2 and 3 together comprised 88.8 ± 1.4% of all 
lymphocytes recovered from the rotor. In fraction 4 and 5 the majority 
of the macrophages (83.8 ± 11.9%) were present, and granulocytes were 
found predominantly in fraction 5. The lymphoid cells in these 2 
fractions were mainly plasma cells and large lymphocytes. Fraction 6 
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represented a mixture of granulocytes, monocytes and lymphocytes with a 
low viability of 42.4 ± 10.1Й, representing 2.7 ± 2.45« of all elutriat­
ed cells. 
In table 2 the absolute number of total cells, lymphocytes, granulo­
cytes and macrophages in the different fractions are shown. After elu-
triation, 71.7 ± 15.1% of the total cells loaded were recovered. Of the 
input lymphocytes, granulocytes and macrophages respectively 72.5%, 
62.4X ad 61.7% were recovered. 
Table 2. Absolute number of lymphocytes, granulocytes and macrophages 
in the different fractions. 
Total c e l l numbei 
χ 10b 
Un f r a c t i o n a t e d 
mater ia l 
Fract ion 
1 
2 
3 
4 
5 
6 
250.5 
5.2 
106.9 
25.1 
17.3 
20.7 
3.B 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
2.6 
0.9 
24.8 
4.3 
6 . 7 
10.4 
4 . 6 
• Lymphocytes 
χ 10b 
202.9 ± 
5.2 ± 
106.9 ± 
24.2 ± 
7.3 ± 
2.7 ± 
0.Θ ± 
26.3 
0.96 
24.θ 
4.0 
2.θ 
2.2 
0.7 
Granylc 
χ 106 
28.7 + 
-
-
_ 
2.0 ± 
13.9 ± 
2.0 ± 
jcytes 
23.1 
2.3 
6.4 
1.5 
Macrophages 
χ 106 
18.9 ± 7.7 
-
-
0.5 ± 0.3 
7.6 ± 2.4 
4.0 ± 3.3 
0.5 ± 0.4 
DISCUSSION 
Counterflow centrifugation has been shown to be an efficient procedure 
for the isolation of human lymphocytes and monocytes from peripheral 
blood. Sanderson et аІ.^іЮ were the first to separate mouse spleen 
cells by counterflow centrifugation. They frequently encountered the 
problem of plug formation in the apex of the separation chamber, which 
they attributed to the low temperature (40C) at which the cells were 
separated. We have met the same problem in fractionating human spleen 
cells by counterflow centrifugation. 
Initially the standard Beekman chamber was used. In 12 out of 16 se­
parate experiments, cell separation was hampered by pelleting of cells, 
which formed a plug at the inflow side of the separation chamber. This 
impeded medium flow and resulted in poor cell separations and recover­
ies. 
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When the medium and centrifuge temperature were kept at 2CPC during 
elutriation pelleting did not disappear. Replacement of the glucose-PBS 
by HBBS with calcium and magnesium and the addition of DNase (0.05 
mg/ml) to the elutriation medium did not contribute to the solution of 
this problem. When the Sanderson chamber was used instead of the Beck-
man chamber, the same difficulty was encountered in 5 out of 10 experi­
ments during loading of cells at a rotor speed of 2870 rpm and medium 
flow rate of 12 ml/min. Lowering the rotor speed and medium flow rate 
in such a way that no cells were eluted during introduction did not 
provide an improvement. However, when the Sanderson and Beekman cham­
bers were combined in 1 rotor, cell crowding was minimized near the 
inflow side of the Sanderson chamber so that pelleting was prevented. 
We found the use of 2 chambers of the same type in 1 rotor as des­
cribed by Grabske^ to be less beneficial in view of their identical 
separation characteristics. Use of the equipment combined with the cell 
recognition device which allowed continuous monitoring of the elutria-
tor output permitted collection of 88.8 ± 1.4% of all lymphocytes re­
covered from the rotor in 2 pooled fractions with a purity of> 98л. The 
macrophage fractions, however, were mixed with granulocytes, indicating 
that the elutriation profiles of both cell types overlap. The presence 
of granulocytes can be reduced considerably by a modified elutriation 
technique described for peripheral blood by Figdor et al.20, in which 
the density of the elutriation medium was increased stepwise by the ad­
dition of Percoli after the lymphocytes had been eluted. 
Our results indicate that large numbers of lymphocytes with high 
purity may be obtained from human spleen by counterflow centrifuga-
tion, with concomitant enrichment for splenic macrophages. 
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CHAPTER 3 
DEPRESSED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY OF SPLENIC AND PERI­
PHERAL BLOOD LYMPHOCYTES IN HODGKIN'S DISEASE AND THE IN VITRO MODULA­
TION BY INTERFERON AND INTERLEUKIN-2 
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SUMMARY 
Antibody-dependent cellular cytotoxicity (ADCC) was studied in sple­
nic and peripheral blood lymphocytes of patients with Hodgkin's disease 
(HD) and controls. This function was investigated after purification of 
the lymphocytes by counterflow centnfugation. ADCC was determined by 
DNA flow cytometry, using antibody-coated chicken red blood cells 
(CRBC) as targets. Compared to controls, a significantly depressed ADCC 
was found in both splenic lymphocytes (p < 0.01) and peripheral blood 
lymphocytes (p < 0.02) of patients with HD. No relationship was found 
between the percentage of lysis of CRBC and stage of disease, presence 
of В symptoms and absolute number of peripheral blood lymphocytes. Re­
combinant human interferon-alpha 2 did not enhance ADCC of splenic 
lymphocytes obtained from HD patients or controls. Splenic and periphe­
ral blood lymphocytes appeared in some patients unresponsive to boost­
ing by interleukin-2. 
INTRODUCTION 
The impairment of various cell-mediated immunological functions in 
patients with Hodgkin's disease (HD) is a well-known and consistent 
feature^»2»3. Much attention has been paid to functional Τ cell de-
fects^^jó,?^ suppressor cell abnormalities8»9»10 and immunomodu-
lation by serum factors?»'''' in order to elucidate the mechanisms con-
tributing to the impaired immunity in HD. Although natural killer (NK) 
and killer (K) cells are increasingly presumed to play an important 
role in tumor growth inhibition12»15»^, NK activity and antibody-de-
pendent cellular cytotoxicity (ADCC) have not been investigated exten-
sively in HD. Besides in the inhibition of neoplastic growth, ADCC, me-
diated by different cell types, such as lymphocytes, monocytes and gra-
nulocytes, is an efficient immunological defense mechanism participat-
ing in allograft rejection15 and parasite destruction1^. The ef-
fector lymphocytes of ADCC are supposed to be a subset of a Fc-re-
ceptor-beanng, third population of human mononuclear cells, also call-
ed large granular lymphocytes1?»1^. These lymphocytes possess ADCC 
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properties to antibody-coated tumor cells and are to a lesser extent 
also capable to lyse in vitro antibody-sensitized erythrocyte targets 
such as chicken red blood cells (CRBC)^. 
The data concerning the ADCC activity in HD are scarce and, moreover, 
partially conflicting7»20m in this study we have measured ADCC on 
lymphocytes isolated from peripheral blood and spleens by counterflow 
centrifugation (CFC). Lymphocyte mediated ADCC (Ly-ADCC) was analysed 
in peripheral blood lymphocytes of 16 patients with HD and 12 normal 
controls and in splenic lymphocytes obtained from 11 HD patients and 
6 controls. Furthermore, the effect of recombinant human interferon 
alpha-2 and interleukin-2 on the effector cell function was tested in 
vitro. 
MATERIALS AND METHODS 
Patients and controls. 
Peripheral blood lymphocytes were obtained from 15 newly diagnosed 
and untreated patients with histologically proven HD and 1 patient in a 
relapse. A group of 12 healthy individuals of similar age and sex dis­
tribution served as controls. Splenic lymphocytes were isolated from 
spleens of 11 patients with HD, who underwent staging laparotomy, 
whereas 6 spleens from individuals with accidental splenic rupture 
served as a control group. Staging procedures were carried out accord­
ing to the criteria recommended at the Ann Arbor Conference^. The 
histologic material was classified according to the Rye Conference mo­
dification of the Lukes-Butler classification^. Age, sex, histology 
and stage of the HD patients are listed in tables 1 and 2. 
Lymphocyte isolation. 
Peripheral blood lymphocytes were isolated with the use of cell scat­
ter monitored counterflow centrifugation (elutriation)23,24# 
Splenic lymphocyte suspensions were prepared as previously describ-
ed25. Briefly, after cutting into small pieces, the splenic tissue 
fragments were gently pressed through a 75 μπι nylon filter. After incu-
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Table 1. Clinical data of the patient group in which peripheral blood 
Ly-ADCC was determined. 
No 
1 
2 
3 
и 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Age 
74 
17 
24 
36 
23 
26 
39 
39 
67 
26 
49 
56 
17 
15 
21 
32 
Sex 
M 
F 
F 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
F 
F 
M 
Stage 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
III в 
II B/PS 
III A/PS 
π в 
III в 
IV в 
IV В (R) 
II 
I А 
II A/PS 
II A/PS 
I А 
IV В 
III А 
III А 
III А 
II 
III 
II 
II 
Histology 
MC 
NS 
NS 
NS 
MC 
MC 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
MC 
NS 
MC 
CS = clinical stage; PS = pathologie stage; R = relapse. 
A/B = without/with constitutional symptoms. 
NS = nodular sclerosis; MC = mixed cellularity. 
Table 2. Clinical data of the patient group in which splenic Ly-ADCC 
was determined. 
No 
1 
2 
3 
*4 
5 
6 
7 
θ 
9 
10 
•11 
Age 
1Θ 
17 
24 
20 
24 
45 
57 
31 
62 
18 
29 
Sex 
M 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
PS 
II 
II 
III 
III 
II 
I 
I 
I 
II 
IV 
II(R) 
Histology 
NS 
NS 
NS 
LP 
NS 
LP 
NS 
MC 
LD 
MC 
MC 
Spleen : 
_ 
_ 
+ 
+ 
-
-
-
-
+ 
+ 
-
•treated with mantle field irradiation prior to staging laparotomy. 
R = relapse; PS = pathologic stage. 
NS = nodular sclerosis; MC = mixed cellularity. 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
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bation for 30 min at 37°С in Tris-buffered Minimum Essential Medium 
(MEM) supplemented with 0.05 mg/ml DNAse and 5% heat-inactivated pooled 
human serum, the cell suspension was layered on a discontinuous Percoli 
dual density gradient (respectively 1.045 and 1.077 g/ml). Intact cells 
were recovered from the 1.077 interphase, washed once and introduced 
into the elutriator. A combination of the standard Beekman and the San­
derson separation chambers was used on line in 1 rotor. While the flow 
rate was kept at a constant rate of 12 tnl/min a stepwise decrease in 
rotor speed allowed the cells to emerge from the separation chambers. 
Use of this equipment combined with continuous monitoring of the elu­
triator output by means of cell scatter analysis permitted collection 
of ΘΘ.Θ ± 1,4S of all lymphocytes with a purity of > 98%. 
Antibody-dependent cellular cytotoxicity (ADCC) assay. 
Ly-ADCC was performed as described by Atallah et al.26, Freshly 
prepared chicken red blood cells (CRBC), sensitized with a rabbit anti-
CRBC IgG (United States Biochemical Corp. Cleveland/Ohio, USA) in a 
final dilution of 1 : 40.000, were used as target cells. Since CRBC 
contain 2.5 pg of DNA per nucleus and human lymphocytes about 6 pg of 
DNA per nucleus, the effector and target cell nuclei can be distin­
guished easily by DNA-flowcytometry after staining with hypotonic ethi-
dium bromide (EB). 
Lymphocytes were resuspended in MEM at a concentration of 8 χ 10°/ 
ml and mixed with equal volumes of CRBC (concentration 4 χ 10 6/ml). Of 
this mixture 100 μΐ supplemented with 50 μΐ MEM and either 50 μΐ rabbit 
anti-CRBC Ig or MEM (blank) were cultured in triplicate in 800 μΐ 
round-bottom tubes (Micronic PPN tubes, Flow Laboratories, Amstelstad 
B.V., Zwanenburg, The Netherlands) for 16 hours at 370C. The incubation 
was stopped after 16 hours by adding 600 μΐ hypotonic ethidium bromide 
(ЕВ: 0,1й trisodium citrate and 25 mg/liter ethidium bromide; 30 mos-
mol/kg, pH 7.6) supplemented with 0,1£ Triton X-100 (v/v) to each 
tube. After mixing DNA-analysis was performed with a flow cytometer 
(ICP-11, Phywé, Gò'ttingen, FRG). The DNA-histograms were used to cal-
culate Ly/CRBC ratios. The percentage CRBC lysis due to lymphocyte 
cytotoxicity was calculated according to the formula: 
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Ly/CRBC - Entibody 
% k i l l = 100 - ( ) χ 100. 
Ly/CRBC + aitibody 
Also c u l t u r e s were c a r r i e d out, in which recombinant human i n t e r f e r o n -
alpha 2 or i n t e r l e u k i n - 2 were added and cocultured during 16 hours. 
Recombinant human interferon-alpha 2-arg (IFN-a2). 
IFN-a2, k indly provided by Boehringer Ingelheim (Ingelheim am Rhein, 
FRG), was added in a volume of 50 μΐ t o 100 μΐ of lymphocyte-CRBC mix­
ture at a f i n a l concentration of 1000 units/ml supplemented with e i ther 
50 μΐ rabbi t anti-CRBC IgG or MEM ( b l a n k ) . 
Interleukin-2 (IL-2). 
Delectinated, serum- and protein-free IL-2 (Cellular Products Inc., 
Buffalo, NY, USA) was added in a volume of 50 μΐ to 100 μΐ of lympho­
cyte-CRBC mixture at a final concentration of λ0% (v/v) supplemented 
with either 50 μΐ rabbit anti-CRBC IgG or MEM (blank). 
Statistics. 
The Wilcoxon two-sample test was used to compare the results of ADCC 
between patients with HD and normal controls. To evaluate the influence 
of IFN-a2 and IL-2 on ADCC the Wilcoxon signed rank test was used. Ρ < 
0.05 was considered to be significant. 
RESULTS 
Peripheral blood lymphocytes. 
In both the patient and the control group, counterflow centrifugation 
(CFC) of the peripheral blood leucocytes resulted in an excellent de­
pletion of monocytes. The purity of the lymphocyte suspension exceeded 
for both groups 98.5 ± 1.55», whereas the yield of all lymphocytes elu­
triated was 91 ± 4S and 92 ± 3Ä for the patient and control groups res-
pectively. 
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Normal H D 
> - p< 0 02 — 
Fig. 1. Peripheral blood Ly-ADCC of normal controls and patients with 
Hodgkin's disease (HD). 
A significantly reduced killing capacity (P < 0.02) was observed in 
HD (11.В + 8.2Й) compared to normal controls (18.6 ± 5.8%) (Fig. 1 ) . 
There was no correlation between the levels of cytotoxicity and either 
the stage of the disease or the presence of В symptoms. In patients 
with limited disease (stage I/II) a mean percentage of lysis of 10.5 ± 
10% was observed versus 12,6 ± 7.5% in patients with advanced disease 
(stage III/IV), and 9.0 ± 7.0% in patients without В symptoms versus 
14.6 + 8.8л in patients with В symptoms. The absolute number of peri­
pheral blood lymphocytes was not related to killing capacity (r = 
0.31). As shown in Fig. 2, addition of IFN-a2 in a final concentration 
of 1000 units/ml led to a significant enhancement of ADCC in all pa­
tients (a rise from 11.8 ± 8.2% to 20.4 ± 8.9%; ρ < 0.01) and controls 
(a rise from 18.6 ± 5.8% to 26.5 ± 6.4%; ρ < 0.01). The percentage in­
crease in cytotoxicity was comparable in HD and controls. The addition 
of IL-2 10% (v/v) to the ADCC assay culture caused a significant enhan­
cement of cytolytic activity in all controls (from 18.6 ± 5.8% to 35 ± 
6.2%; ρ < 0.01). In contrast, 4 out of 16 patients, all with low ADCC 
levels, failed to show increment of cytotoxicity in response to IL-2. 
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F i g . 2. I n f l u e n c e o f IFN-a2 and IL-2 on p e r i p h e r a l b l o o d Ly-ADCC i n 
normal c o n t r o l s and p a t i e n t s w i t h H o d g k i n ' s d i s e a s e (HD). 
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F i g . 3 . ADCC o f s p l e n i c lymphocytes i n normal c o n t r o l s and p a t i e n t s 
w i t h H o d g k i n ' s d i s e a s e ( H D ) , and t h e i n f l u e n c e o f IFN-a2 and I L - 2 . 
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Splenic lymphocytes. 
Purity and yield of splenic lymphocytes, obtained by CFC, were simi­
lar in both groups. Of all lymphocytes recovered after CFC, 84.8 ± 3.2% 
and 85.9 ± 4.0%, from the patient and control group respectively, were 
collected in one fraction with a purity in both of > 97%. The killing 
capacity of the isolated splenic lymphocytes was substantially decreas­
ed (p < 0.01) in HD patients compared to controls (4.4 ± 5.1?ί versus 
19.0 ± 5.2%; Fig. 3). Only patients no. 1 and 2 exhibited cytotoxicity 
levels above 5%. Enhancement by IFN-a2 was minimal or lacking in the 
splenic lymphocytes from both the HD patients and controls. All control 
splenic lymphocytes showed an increment of kill after addition of IL-2 
(p < 0.05). In HD splenic lymphocytes the observed increase was sta­
tistically not significant. Three out of 11 splenic lymphocyte speci­
mens did not show any increment at all. In these 3 cases the spleen was 
involved by the disease. 
DISCUSSION 
Antibody-dependent cellular cytotoxicity (ADCC) is an immunological 
defense mechanism, in which natural or induced antibodies cooperate 
with effector cells. It can be mediated by a variety of cell types, 
such as lymphocytes, monocytes and granulocytes. In vitro measurements 
of ADCC therefore require optimal purification of the effector cell 
type under study. In this study we used lymphocytes purified by means 
of continuously cell-scatter monitored counterflow centrifugation 
(CFC) 2 3» 2 4» 2 5. CFC has been described by De Vries et al. 2 7 to en­
rich for cells mediating natural killing (NK) in the large sized lym­
phocyte fractions. Since ADCC and NK are believed to be mediated by the 
same effector cells or at least by overlapping subsets or cells at dif­
ferent differentiation stage, it would be obvious to use CFC for en­
richment of these effector cells. On the other hand augmentation of NK 
activity by cytokines is partly due to recruitment of "pre-NK" cells, 
which reside in the small and medium sized lymphocyte fractions2'» 
28. Moreover, in a recent report further heterogeneity among NK cells 
residing in a novel effector population devoid of large granular lym-
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phocyte (LGL) characteristics but mediating highly potent NK-like cyto­
toxicity has been documented29,30# With regard to the possible in­
volvement of various kinds of effector cells we have used the unfrac-
tionated lymphocyte suspension in the ADCC assay. 
Ly-ADCC against rabbit antibody-sensitized CRBC in normal individuals 
has been reported to be reproducible and independent of age and sex. 
Between individuals, however, significant differences were found to 
exist3"!. Τ cell ADCC against IgG-coated 51Cr-labeled CRBC in HD has 
been observed in the normal range in most patients, although Τ cell 
ADCC in patients with involved spleen was higher compared to those in 
whom spleen was not involved7»20. Kohl et al.'2 using monocyte de­
pleted lymphocytes as effector cells and herpes simplex virus-infected 
target cells detected no defects m Ly-ADCC in five HD patients studied 
in a prospective longitudinal fashion at the time of diagnosis, after 
staging laparotomy, during and after therapy. In HD patients ADCC of Τ 
and non-T splenic lymphocyte subpopulations were not different from 
peripheral blood Τ and поп-T cell ADCC20. Comparisons with control 
spleens were not described. Our results are in contrast with these ob­
servations. In both the splenic and peripheral blood lymphocytes from 
HD patients ADCC turned out to be depressed in comparison to controls. 
An explanation for this discrepancy may be the difference in cell sepa­
ration technique and the methodology of ADCC measurement. The depressed 
ADCC in vitro suggests a functional defect of a lymphocyte subset, 
which might reflect a relevant phenomenon in vivo, contributing to the 
impaired immunity in HD. Since the ADCC of the splenic lymphocytes is 
even lower than that of the peripheral blood lymphocytes, the seques­
tration of lymphocyte subsets with ADCC properties in the spleens 
appears unlikely. 
Recent data have indicated that the activity of cells mediating NK 
and ADCC are subject to considerable regulation. Interferon (α,β,γ) 
33,34
 anc
j IL-235 augment the cytolytic function of these effector 
cells. In HD in vitro leukocyte interferon production in response to a 
viral stimulus appeared to be either normal3" or depressed in stage 
IV patients only37. Ford et al.38 observed in HD a defect in IL-2 
production, whereas the ability of Τ lymphocytes to respond to exoge-
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nous IL-2 in vitro was unimpaired. Our data show a complete absence of 
IL-2 responsiveness of peripheral blood and splenic lymphocytes in some 
of the HD patients studied. There are some possibilities for this fin­
ding to be entertained. The responding cells could be refractory to 
IL-2 because of a reduced IL-2 receptor density on their membranes or 
there might be a defect at the level of the IL-2 receptor interaction 
site. The mechanism of induction of activated IL-2 receptors in cytoly­
tic cells is unknown. Surprisingly, the splenic lymphocytes from HD pa­
tients and controls were mainly unresponsive to IFN-a2 in contrast to 
the peripheral blood lymphocytes. An explanation for this unresponsive­
ness is hardly be given, maybe these cells are at a different stage of 
differentiation compared to peripheral blood lymphocytes, not suscepti­
ble for activation by interferon. Further investigations are needed 
to explore whether the impaired ADCC in HD is caused by a defect in the 
effector cell itself or in its humoral or cellular regulating mecha­
nism. 
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CHAPTER 4 
NATURAL KILLER CELL ACTIVITY OF LYMPHOCYTES FROM SPLEEN AND PERIPHERAL 
BLOOD OF PATIENTS WITH HODGKIN'S DISEASE 
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SUMMARY 
Natural killer (NK) cell activity of splenic and peripheral blood 
lymphocytes from patients with untreated Hodgkin's disease (HD) was 
evaluated using K562 cells as targets. NK activity of peripheral blood 
lymphocytes from 23 patients was not different from normal controls. 
When, however, NK activity was examined in relation to the stage of the 
disease or the presence of В symptoms, patients with advanced disease 
(stage III/IV) or with В symptoms demonstrated a significantly decreas­
ed NK activity in comparison to those with limited disease (stage I/II) 
or without В symptoms. Purified splenic lymphocytes from 9 patients 
with HD displayed an enhanced NK activity compared to control splenic 
lymphocytes. In 2 cases of HD with massive disease involvement of the 
spleen, the splenic lymphocytes showed an almost complete absence of NK 
capacity. 
INTRODUCTION 
Patients with untreated Hodgkin's disease (HD) commonly appear to 
have impaired cellular immunity, as recently reviewed by Kumar and Pen­
ny^. Investigations into the mechanisms of immunological impairment 
have revealed a complex of abnormalities, especially intrinsic Τ cell 
defects have been documented extensively^»'. Far less data are avail­
able on the contribution of natural killer (NK) cells to the impaired 
immunity in HD. NK cells include a subset of peripheral blood lympho­
cytes, which are considered to play an important role in natural host 
defense against cancer and infectious diseases^»^. Circumstantial 
evidence exists that these cells display also regulatory effects on Τ 
cell proliferation^ and suppression of immunoglobulin production by В 
cells?. 
In HD NK activity against K562 target cells8 has been reported to 
be depressed using unseparated peripheral blood mononuclear cells 
9,10,11,12
 o r
 j lymphocytes'"
 f whereas normal^ or even slightly 
enhanced^ NK activity was found in monocyte-depleted lymphocytes. 
The data reported on NK activity of spleen cells from HD patients are 
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even more conflicting. Gupta and Fernandes"" found splenic Τ and 
non-T cell NK activity not significantly different between involved and 
non-involved groups. Ruco et аІ.Ю, using spleen cells depleted of 
monocytes and macrophages by adherence, reported an increase in cyto­
toxicity in HD positive and a decrease in HD negative splenic tissue, 
compared to controls. In contrast, Al Sam et al.""* observed spleen 
cells isolated from HD involved spleens and not depleted of monocytes 
and macrophages to be less cytotoxic than cells from HD uninvolved 
spleens. Moreover, NK activity in uninvolved spleens was found signifi­
cantly increased in comparison to normal controls. 
Since human blood monocytes have been shown to be able to kill K562 
cellsl^jlfï,
 anc| adherent cells have been associated with suppression 
of NK activity in cancer patients, it appears of interest to evaluate 
NK capacity in HD using purified lymphocytes. In this study we measured 
NK activity of highly purified lymphocytes isolated from the peripheral 
blood of 23 patients and from the spleen of 11 patients with HD, using 
Cr-labeled K562 cell targets. The results were compared to those ob-
tained in normal controls. 
MATERIALS AND METHODS 
Patients and Controls. 
Peripheral blood lymphocytes (PBL) of 22 newly diagnosed patients 
with histologically proven HD and of 1 patient with a relapse were stu-
died and compared with a group of 15 healthy controls of similar age 
and sex distribution. Splenic lymphocytes were obtained from 11 spleens 
of patients with HD and from 6 control spleens of subjects with acci-
dental splenic rupture. Staging procedures were carried out according 
to the criteria of the Ann Arbor Conference^. The histologic classi-
fication used was that of the Rye Conference modification of the 
Lukes-Butler classification^O. The clinical data of both groups are 
summarized in tables 1 and 2. 
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Table 1. Clinical data of the patient group in which NK activity of 
peripheral blood lymphocytes was determined. 
Age (years) 
Patients Mean Range 
Female 
Male 
7 
16 
36 
36 
18-62 
18-74 
C l i n i c a l stage 
Stage I I I I I I IV η 
3 
4 
7 
12 
11 
Histology: Nodular sclerosis 13; mixed cellularity 4; lymphocytic pre­
dominance 5; lymphocytic depletion 1. 
Table 2. Clinical data of the patient group in which NK activity of 
splenic lymphocytes was determined. 
No Age Sex PS Histology Spleen involvement 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
18 
17 
24 
20 
24 
45 
57 
31 
62 
18 
20 
M 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
I I 
11 
I I I 
n i 
I I 
I 
I 
I 
I I 
IV 
I I (R) 
NS 
NS 
NS 
LP 
NS 
LP 
NS 
MC 
LD 
MC 
MC 
+ (minor) 
+ (minor) 
+ (major) 
+ (major) 
* treated with mantle field irradiation prior to staging laparotomy. 
R = relapse; PS = pathologic stage; 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
Isolation of lymphocytes. 
Lymphocytes were isolated from peripheral blood by a method described 
by De Pauw et al.21. Briefly, monocytes and granulocytes were removed 
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from defibnnated venous blood by nylon wool filtration at a constant 
flow rate. The filtrate was depleted of erythrocytes by density centn-
fugation. The isolated lymphocyte suspension was washed once and resus­
pended in Tns-buffered Minimum Essential Medium supplemented with IOS 
(v/v) heat-inactivated pooled human serum (MEM-PHS). 
Lymphocytes from human spleen were purified by counterflow centnfu-
gation (elutnation) employing two different chambers on line, as re­
ported previously22. Briefly, after the preparation of a single cell 
suspension the cells were subjected to a discontinuous Percoli dual 
density gradient (1.045 and 1.077 g/ml respectively) centnfugation 
(800 χ g; 15 min; 2CPC). After removing dead cells and cell fragments 
at the 1.045 interphase, intact cells were recovered from the 1.077 in­
terphase, washed once and introduced into the elutnator rotor (Beekman 
J2-21 С centrifuge equipped with a JE-6 elutnator rotor with a combi­
nation of the standard Beekman and the Sanderson separation chamber on 
line). The gradual diminution of centrifugal speed at a constant coun­
terflow rate of 12 ml/min allowed cells to emerge from the separation 
chambers. Optimal purification of lymphocytes was established by means 
of scatter analysis of the effluent^, enabling continuous monitoring 
of cell size and number. This method permitted collection of 88.θ ± 
1.4% of all lymphocytes recovered from the rotor with a purity of > 
98%. After collection, the cells were resuspended in MEM-PHS. 
Natural_killer_(NlO_assay. 
NK activity was tested against the human erythromyeloid cell line 
«562". Target cell labeling was performed by incubating 5 χ 10 cells 
with 100 μΟι of sodium ( Cr) Chromate (Radiochemical Centre Amersham, 
UK) for 60 min at 37°С After three washes, the cells were resuspended 
5 
in MEM at a concentration of 1 χ 10 /ml. Effector cells were resuspend­
ed in MEM-PHS at a concentration of 4 χ 106/ml, 2 χ 106/ml and 1 χ 
10 /ml. Of each concentration 100 μΐ were added to 100 μΐ of target 
cells in conical bottomed microtitre plates (Flow laboratories Inc., 
McLean, Virg, USA). 
All incubations at the different effector/target (E/T) ratio's of 
40:1, 20:1 and 10:1 were carried out in triplicate. The plates were 
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centrifuged at 40 g for 2 min and subsequently incubated at ЗЯС. After 
4 hours the microtitre plates were centrifuged at 500 g for 5 min and 
100 μΐ of the supernatants were collected and counted for Сг-геіеазе 
in a gamma scintillation counter. 
The percentage specific release was calculated by the formula: 
E-S 
% specific release = χ 100 
T-S 
E = mean (of triplicate) counts per min (с.p.m.) released in the pre­
sence of effector cells. 
5 = mean c.p.m. spontaneously released by target cells incubated with 
medium instead of effector cells. 
Τ = mean c.p.m. total release after lysis of targets with lysing rea­
gent (Zaponin, Coulter Electronics Limited, Northwell Drive, Luton 
Beds, UK). 
The greatest increase in activity was noted at an E/T ratio of 40:1 and 
therefore these results are presented. 
Statistics. 
The Wilcoxon two-sample test was used to compare the results, which 
are given as means ± standard deviation. 
RESULTS 
The purity of the lymphocyte suspensions isolated from peripheral 
blood by nylon wool filtration and density centrifugation were similar 
in the control and the patient group and varied from 94-99% with a mean 
of 97K + 2л. The contamination by monocytes ranged from 0 to 1.5515. The 
purity of the splenic lymphocyte suspensions obtained by CFC was also 
similar for both HD patients and controls (9Θ ± 1.05»), 
As illustrated in fig. 1, peripheral blood lymphocytes of normal sub­
jects exhibited a mean cytotoxicity of 28.1 ± 10.7%. Mean NK activity 
for the 23 HD patients was 29.4 ± 11.5%, not different from the control 
group. When, however, the data were further examined in relation to the 
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Fig. 2. NK activity of peripheral blood lymphocytes in relation to 
absence (A) or presence (B) of constitutional symptoms and to the stage 
of disease. 
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stage of the disease or the presence of В symptoms (Fig. 2) NK activity 
of patients in stage I/II (36.3 ± 10.8%) or without В symptoms (31.8 ± 
11.4Й) was enhanced, and that of patients in stage III/IV (24.1 ± 9.3%) 
or with В symptoms (21.8 ± 6.3л) was decreased, although not signifi­
cantly, in comparison to the control group (28.1 ± 10.7л). Patients in 
stage III/IV and patients with В symptoms had significantly decreased 
NK activity compared with those in stage I/II (24.1 ± 9.3л versus 36.3 
+ 10.8S; ρ < 0.02) and without В symptoms (21.8 ± 6.35a versus 31.8 + 
11.4%; ρ < 0.005). 
Specific lysis C/o ) 
N=6 
60 
N = 11 
40 -
20 
Normal HD 
Fig. 3. NK activity of splenic lymphocytes from normal controls and 
patients with Hodgkin's disease (HD). 
The data of NK activity in the splenic lymphocytes from HD patients 
and controls are shown in Fig. 3. Mean cytotoxicity of the splenic 
lymphocyte suspension of HD patients was higher (34.3 + 18.95Í) compared 
to control spleens (21.6 ± 6.4л), although the difference was not sig­
nificant mainly because of the small number of spleens analysed and the 
large interindividual variation. Lymphocytes from two spleens with mas­
sive involvement showed an almost complete absence of NK activity. One 
of these spleens was removed for diagnostic reasons (no. 9 ) , the other 
for debulking (no. 10). In cases no. 3 and 4 involvement was minimal 
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consisting of one nodule with a diameter of 3 mm. Cytotoxicity in these 
cases did not differ from spleens without disease involvement. When 
both spleens with heavy HD involvement were left out, NK activity of 
the HD group reached a significant enhanced level in comparison to the 
control group (41.2 ± 12% vs 21.6 ± 6Λ%', ρ < 0.05). 
DISCUSSION 
In Hodgkin's disease (HD) the contribution of NK cells to the impair­
ment of immunological functions has been hardly investigated, especial­
ly relatively few studies have recorded spontaneous cell-mediated cyto­
toxicity of lymphoid cells extracted from spleens and lymph nodes of 
patients with this disease. 
The normal NK cell activity of peripheral blood lymphocytes, which 
was measured in 23 HD patients is in agreement with the observations of 
Rotstein et al. 1 5 in 12 HD patients and of Kohl et al.16 i
n
 5 HD 
patients. We observed a significantly lower NK cell activity in pa­
tients with constitutional symptoms or advanced disease compared to 
asymptomatic patients and patients with limited disease. Decreased NK 
cell activity was described by Tursz et al.9 in 22 patients, by Ruco 
et al.Ю in 9 patients, by Hawrylowicz et al.H in 20 patients and 
by Levy et al. 12 in 30 patients. These results differ from our data 
and may be explained by more advanced disease in the patient group in­
vestigated or by contamination of the effector lymphocyte population by 
monocytes due to different lymphocyte isolation. Interactions between 
lymphocytes and monocytes influencing final NK activity in the assay 
system cannot be excluded in these studies. Furthermore, an absolute 
monocytosis is not infrequently noted in HD, especially in advanced 
stages^, which has as a consequence a relatively reduced number of 
lymphocytes in the effector peripheral blood mononuclear cell popula­
tion of patients with advanced compared to localized disease. 
In 9 cases the splenic lymphocytes of HD patients showed a stronger 
NK cell activity than in controls. NK cell activity of 2 cases with 
massive involved spleen was virtually absent. Al Sam et al.16 report­
ed the same findings, whereas Ruco et аІ.Ю detected consistently 
higher NK cell activity in HD positive spleens compared with HD nega-
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tive spleens. Gupta and Гетапаез 1" stated NK activity not to be dif­
ferent between involved and non-involved groups. This inconsistency may 
be due to differences in type and stage of HD and differences in sple­
nic involvement. The normal or even slightly enhanced NK capability of 
peripheral blood lymphocytes from asymptomatic patients and patients 
with localized disease combined with the enhanced cytotoxicity display­
ed by uninvolved HD spleens in our study is in favour of local splenic 
activation rather than sequestration of NK-capable cells. Interesting­
ly, we registered simultaneously an enhanced NK cell activity and de­
pressed antibody dependent cellular cytotoxicity (ADCC)25 in splenic 
lymphocytes from HD patients. This would indicate functional differen­
ces, whereas substantial evidence from the literature^,27 attributes 
both functions to the same lymphocyte subpopulation. The almost com­
plete loss of NK capability displayed by lymphocytes from massively 
involved spleens may point to a change in lymphocyte activation by 
tumor involvement of the splenic tissue, resulting in an impairment of 
NK capacity. Our data may reflect an activation of NK cells early in 
the disease with progressive deterioration of cell-mediated cytotoxic 
functions as Hodgkin's disease progresses. 
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CHAPTER 5 
INFLUENCE OF INTERLEUKIN-2 AND RECOMBINANT HUMAN INTERFERONS ON NATURAL 
KILLER CELL ACTIVITY OF SPLENIC AND PERIPHERAL BLOOD LYMPHOCYTES IN 
HODGKIN'S DISEASE 
J.Th.P. Janssen, В.E. de Pauw, J.В.J.M. Smeulders, J.M.C. Wessels, 
D.J.Th. Wagener and С. Haanen 
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SUMMARY 
The ability of interleukin-2 (IL-2) and recombinant human interfe-
ron-alpha 2 (IFN-a2) and interferon-gamma (IFN-γ) to modulate natural 
killer (NK) cell activity of purified lymphocytes from peripheral blood 
and spleens was analysed in patients with Hodgkin's disease (HD) and 
normal controls. Except for the significantly higher (p < 0.05) aug­
mentation of NK activity by IL-2 in peripheral blood lymphocytes (PBL) 
from HD patients in comparison to normal controls, no major differences 
between HD patients and controls were observed. IFN-γ failed to enhance 
NK capacity of PBL and splenic lymphocytes (SL) from HD patients and 
controls. Even after prolonged incubation with IFN-γ the level of NK 
activity in SL was unaffected. Addition of IFN-a2 into the 4-hr NK as­
say induced enhancement in NK activity of PBL from HD patients and con­
trols, whereas NK activity of SL was unaffected. However, the SL from 
HD patients and controls displayed a comparable increase of lytic acti­
vity after prolonged incubation with IFN-a2. In general, the ability of 
NK cells from HD patients to respond in vitro to exogenous IL-2, IFN-a2 
or IFN-γ was not different from controls. 
INTRODUCTION 
Over the past ten years evidence has been accumulated that interleu-
kins and interferons play a pivotal role in the regulation and media­
tion of several important lymphocyte functions^»2. Both a- and γ-
interferon as well as interleukin-2 (IL-2) have been described to sti­
mulate natural killer (NK) cell activity of lymphocytes against allo­
geneic tumor cells after in vitro incubation'»^. On the other hand, 
when NK activity is monitored in patients under prolonged treatment 
with interferon, sometimes a decrease is observed after an initial rise 
in activity-*^. The suggestion has been put forward that a dysfunc­
tion of the interferon system or a defective functioning of the lympho-
kine cascade could be related to the occurrence or the course of cer­
tain diseases. In Hodgkin's disease (HD) the Τ cell defect has been 
associated with the impaired ability of peripheral blood mononuclear 
cells to generate IL-2 in vitro after appropriate stimulation^. The 
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capability of peripheral blood leukocytes from patients with Hodgkin's 
disease to synthesize interferon in response to a viral stimulus has 
been reported to be either unimpairedö or defective in patients with 
stage IV disease only^. 
In the present study the in vitro modulation of NK activity of sple-
nic and peripheral blood lymphocytes from patients with HD by IL-2 and 
recombinant human interferons, a-2 and γ, was evaluated to explore to 
what extent the regulation of NK cells in this disease is defective or 
not. 
MATERIALS AND METHODS 
Patients and controls. 
The individuals studied for peripheral blood lymphocytes included 22 
untreated patients with biopsy-proven HD, 1 patient in a relapse and 15 
healthy controls. The clinical data are summarized in table 1. Splenic 
lymphocytes were obtained from 11 spleens of patients with HD and from 
6 control spleens of individuals with accidental splenic rupture. The 
clinical data of this group of HD patients are listed in table 2. The 
histologic classification of the patients with HD was made according to 
the Rye Conference modification of the Lukes-Butler classification^. 
Staging procedures were carried out as recommended at the Ann Arbor 
Conference^. 
Isolation of lymphocytes. 
Peripheral blood lymphocytes (PBL) were isolated from defibrinated 
peripheral blood by nylon wool filtration and Ficoll-Isopaque density 
centrifugation as described by De Pauw et al^2. The isolated lympho­
cyte suspension was resuspended in Tris-buffered Minimum Essential Me­
dium supplemented with 10« (v/v) heat-inactivated pooled human serum 
(MEM-PHS). 
Purification of lymphoid cells from human spleen was performed by 
counterflow centrifugation employing a combination of the standard 
Beekman and the Sanderson separation chambers on line in one rotor, as 
described previously^'. Briefly, after the preparation of a single 
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Table 1. Clinical data of the patient population tested for modulation 
of NK activity of peripheral blood lymphocytes by interferon (a2 and γ) 
and interleukin-2. 
No 
1 
2 
3 
4 
5 
6 
7 
θ 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Age 
74 
1Θ 
23 
62 
20 
55 
62 
26 
1Θ 
20 
45 
22 
69 
29 
57 
31 
18 
32 
20 
23 
51 
62 
72 
Sex 
M 
M 
M 
F 
M 
M 
M 
F 
F 
F 
M 
M 
M 
M 
F 
F 
M 
M 
M 
M 
M 
F 
M 
Stage 
es 
es 
es 
PS 
CS 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
es 
HIB 
IIA/PSII 
IIA/PSII 
III 
IIA/PSII 
IIA 
IIB 
IVA 
IVB 
ΠΙΑ 
lA/PSI 
HIB 
HIB 
IIA/PSII(R) 
IA/PSI 
IA/PSI 
IVB/PSIV 
IIA 
IHA/PSIII 
IVB 
IVB 
IIB 
IVB 
Histology 
MC 
NS 
LP 
LP 
LP 
NS 
NS 
NS 
NS 
NS 
LP 
NS 
NS 
MC 
NS 
MC 
MC 
NS 
LP 
NS 
NS 
NS 
LD 
R = relapse; CS = clinicial stage; PS = pathologic stage. 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
cell suspension and density centrifugation the mononuclear cell suspen­
sion was introduced into the elutriator. A Beekman J2-21 С centrifuge 
was used equipped with a JE-6 elutriator rotor with the two different 
chambers on line. The counterflow rate was maintained constant at 12 
ml/min throughout the procedure. By gradually diminishing the rotor 
speed, cells were permitted to leave the separation chambers mainly 
according to their size. Continuous scatter analysis of the effluent 
enables optimal separation of lymphocytes from monocytes, macrophages 
and granulocytes. This method permits collection of 88.8 ± 1.4Й of all 
lymphocytes recovered from the rotor with a purity of > 96%. After col­
lection, the lymphoid cells were resuspended in MEM-PHS. 
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Table 2. Clinical data of the patient population tested for modulation 
of NK activity of splenic lymphocytes by interferon (a2 and γ) and 
interleukin-2. 
No 
1 
2 
3 
*4 
5 
6 
7 
θ 
9 
10 
»11 
Age 
18 
17 
24 
20 
24 
45 
57 
31 
62 
1Θ 
29 
Sex 
M 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
PS 
II 
II 
III 
III 
II 
I 
I 
I 
II 
IV 
II (R) 
Histology 
NS 
NS 
NS 
LP 
NS 
LP 
NS 
MC 
LD 
MC 
MC 
Spleen 
Involvement 
_ 
-
+ (minor) 
+ (minor) 
_ 
_ 
-
_ 
+ (major) 
+ (major) 
-
* treated with mantle field irradiation prior to staging laparotomy. 
R = relapse; PS = pathologic stage. 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
Natural killer (NK) assay. 
The erythromyeloid cell line К 562 was used as target cells. Effector 
lymphocytes (concentration 4 χ 10 /ml) were added to sodium ( Cr)-
chromate-labeled K562 cells (concentration 2 χ 10 /ml) at an effector-
to-target (E/T) ratio of 40: 1 with and without the addition of a2- or 
γ-interferon or interleukin-2 in a total volume of 200 μΐ in conical 
bottomed microtitre plates (Flow Laboratories Inc., McLean, Virg, USA) 
and incubated at 37°С for 4 hours. All incubations were performed in 
triplicate. Percentage specific cytotoxicity was calculated from the 
formula: 
Release in the test - Spontaneous release 
χ 100 
Maximum release - Spontaneous release 
Spontaneous release was determined from cultures where target cells 
were incubated without effector cells, while maximum release was as­
sessed after detergent treatment of target cells. 
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Recombinant human interferon-alpha-2-arg (IFN-a2). 
Q 
IFN-a2, specific activity 3.2 χ 10 units/mg protein, was kindly 
provided by Boehringer Ingelheim (Ingelheim am Rhein, FRG) and added to 
the cultures at a final concentration of 1000 units/ml. 
Recombinant human interferon-gamma (IFN-γ). 
IFN-γ, produced at Genentech Inc. (San Francisco, CA, USA), specific 
activity 6.θ χ 10^ units/mg protein, was kindly provided by Boeh­
ringer Ingelheim (Ingelheim am Rhein, FRG). Initially it was added to 
the cultures at a final concentration of 1000 units/ml. Since at this 
concentration any influence on NK activity was absent, IFN-γ was added 
at various concentrations of 8000, 2000, 1000 and 500 units/ml. 
Interleukin-2 (IL-2). 
Delectinated, serum- and protein-free IL-2 (Cellular Products Inc., 
Buffalo, NY, USA) was added at a final concentration of 10Й (v/v). 
Overnight incubation of splenic lymphocytes. 
The NK activity of splenic lymphocytes was also assayed after pre-in-
cubation for 18 hours with and without IFN-a2, IFN-γ and IL-2 at con­
centrations comparable to those mentioned above. 
The lymphocytes were cultured at a concentration of 4 χ 10 /ml in 1 
ml MEM-PHS. After overnight incubation cells were washed once and NK 
assay was performed at an E/T ratio of 40:1. 
Statistics. 
The Wilcoxon test for paired observations was used to calculate sta­
tistical differences. The results are expressed as means ± one SD. 
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RESULTS 
NK activity of peripheral blood lymphocytes (PBL) from an overall po­
pulation of HD patients was not different from control subjects (29.U ± 
11.5S versus 2Θ.1 ± 10.1%). Mean cytotoxicity of splenic lymphocytes 
(SL) from HD spleens tended to be higher in comparison to control 
spleens (34.3 + 1В.9Й versus 21.6 ± 6.4Й). 
The effect of IFN-a2, IFN-γ and IL-2 on NK activity of PBL from pa­
tients and sex- and age- matched controls are depicted in Fig. 1. In HD 
patients NK activity expressed as specific lysis of 29.4 ± 11.5% was 
enhanced significantly by IFN-a2 to 40.9 ± 13.6?£ (p < 0.01) and by IL-2 
to 46.5 ± 15.θ (ρ < 0.01). In the controls a similar rise in NK activi­
ty was observed after addition of IFN-a2 (28.1 ± 10.75» versus 42.0 ± 
13.7Й; ρ < 0.01) and IL-2 (28.1 ± 10.1% versus 37.6 ± 9.0Й; ρ < 0.01). 
The percentage of augmentation by IFN-a2 was comparable in controls 
(13.9 ± 5.3й) and HD patients (12.3 ± 9.3S), even when subdivided into 
patients with (11.8 ± 6.1Ж) or without (12.8 ± 11.Ί%) В symptoms and 
into patients in stage I/II (14.8 + 12.8%) or stage III/IV (10.5 ± 
6.Ой). The percentage of augmentation by IL-2 appeared higher in HD 
over controls (19.8 ± 13.1Й versus 10.4 ± 6.6%; ρ < 0.05). Surprising­
ly, IFN-γ, added at the various concentrations, did not affect NK acti­
vity of both the 11 HD patients and the 6 control individuals tested 
which is shown in Fig. 1 for a concentration of 1000 units/ml. 
As is illustrated in Fig. 2, NK activity of freshly isolated SL was 
augmented by IL-2 only, whereas both interferons did not change the NK 
activity level of SL. The percentage of increment by IL-2 was not es­
sentially different between HD (8.5 ± 5.755) and controls (11.7 ± 6.35S). 
To explore whether human SL might be also unsensitive to boosting by 
interferons after longterm incubation, 4 χ 10 б lymphocytes/ml MEM-PHS 
were incubated at З^С for 18 hours without and with IFN-o2 and IFN-γ. 
After 18 hours cells were washed once and NK activity was assayed as 
described for PBL and freshly isolated SL. The results are presented in 
table 3. The lytic activity of the SL dropped after 18 hours incubation 
without interferons or IL-2 in HD from 34.3 ± 18.9% to 6.7 ± 6.6% and 
in controls from 21.6 ± 6.4% to 8.2 ± 6.455. In both groups IFN-a2 dis­
played the ability to augment the lytic activity, in HD up to 15.9 ± 
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Specific lysis!1/.) 
Θ0-
6 0 -
4 0 -
2 0 -
N-15 
• 
• 
• 
* 
* 
* n 
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« 4 
• 
15 
1 
• 
£ Ì 
-Ж* 
m 
Б 
-
« 
t 
• 
10 
• 
Τ 
* 
î 
Normal IFN-a2 IFN-γ 
_ p < 0 O I — . 
IL-2 HD IFN-a2 IFN-γ 
r-1x00001—< 
IL-2 
p<0 01 • 
F i g . 1. Influence of IFN-a2, IFN-γ and IL-2 on NK a c t i v i t y of periphe­
r a l blood lymphocytes in pat ients with Hodgkin's disease (HD) and nor­
mal c o n t r o l s . 
Specific lysis I*/.) 
80 
(0 
2 0 -
Normal IFN-a2 IFN-γ 
ι • p<005 — 
IFN-a2 IFN-γ 
p<001 
IL-2 
F i g . 2. Influence of IFN-a2, IFN-γ and IL-2 on NK a c t i v i t y of splenic 
lymphocytes in p a t i e n t s with Hodgkin'з disease (HO) and normal con­
t r o l s . 
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Table 3. Influence on NK-like activity of splenic lymphocytes by IFN-a2, IFN-γ, and IL-2 after 18 
hours of incubation; dashes indicate not determined. 
HD s o l e e n 
n o . 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Mean 
± SD 
Ρ 
C o n t r o l 
n o . 
1 
2 
3 
k 
5 
6 
Mean 
± SD 
Ρ 
s p l e e n 
Spontaneous 
N K - l i k e 
a c t i v i t y (Ä) 
_ 
5 
6 
3 
11 
11 
7 
2 
1 
0 
22 
6.8 
± 6.5 
6 
1 
11 
3 
18 
11 
8.3 
± 6 .2 
IFN-a 
Щ (». 
30 u n i t s / m l 
) 
15 
21 
7 
21 
36 
8 
20 
2 
0 
31 
1 6 . 
± 1 1 . 
P < 0 . 
14 
9 
14 
16 
22 
39 
1 9 . 
± 1 0 . 
Ρ 
< 0 . 
1 
9 
01 
Ό 
6 
05 
8000 
_ 
_ 
_ 
_ 
_ 12 
5 
2 
1 
0 
24 
7.3 
± 9.2 
7 
0 
9 
3 
15 
12 
7.6 
t 5.6 
-
IFN-
2000 (s 
_ 
_ 
_ 
_ 
-10 
7 
2 
1 
0 
22 
7 . 0 
± 8.3 
7 
2 
9 
3 
17 
14 
8.6 
± 5.9 
-
-γ 
1000 ) 
_ 
_ 
_ 
_ 
_ 13 
β 
4 
1 
0 
26 
8.6 
± 9.7 
7 
2 
10 
4 
18 
13 
9.0 
± 5.9 
-
500 
_ 
_ 
_ 
_ 
_ 15 
7 
1 
1 
0 
21 
T. 
± 8. 
7 
1 
10 
3 
18 
12 
8. 
± 6 . 
-
u n i t s / m l 
5 
7 
Τ 2 
I L - 2 
m (v/v) 
_ 
_ 11 
20 
21 
55 
32 
30 
63 
9 
46 
31.9 
± 19.1 
ρ < 0.01 
18 
25 
16 
49 
50 
81 
39.8 
± 2 5 . 0 
ρ < 0.05 
Os 
-J 
12.OS (ρ < O.Ol) and in controls up to 1Θ.6 ± 10.5% (p < 0.05) respect­
ively. No modulation was observed of the lytic activity in both groups 
by IFN-γ at all concentrations used. IL-2 appeared to have the highest 
boosting efficacy, 31.8 + 19.1% (p < 0.01) for HD and 39.8 ± 25.0% (p < 
0.05) for control spleens. 
DISCUSSION 
The role of the natural killer (NK) cell system in HD is poorly un­
derstood. The main objective of this study was to determine whether a 
defect might be involved in the regulation of NK activity by mediators 
like IL-2 and IFN-<i2 and -γ in HD. Except for a higher sensibility of 
PBL from HD patients for boosting by IL-2, no differences were observed 
in the average capability of modulating NK activity of PBL and SL from 
HD patients and controls by IL-2 and IFN-a2 and -γ. 
Perhaps the most interesting observation made was the complete lack 
of IFN-γ to boost NK activity of PBL and SL from both HD patients and 
controls, even after a prolonged incubation. The use of highly purified 
lymphocytes with optimal depletion of monocytes might offer a feasible 
explanation for this phenomenon. Although enhancement of NK activity by 
IFN-γ is believed to be mediated by a direct activation of the cyto­
toxic cells^»^ in most studies peripheral blood mononuclear cells 
serve as effectors. A tentative hypothesis explaining an indirect 
activation of NK cells by IFN-γ might be the secretion of IL-2 by Τ 
cells activated in response to IL-1, secreted by monocytes and macro­
phages, which in turn are activated by IFN-γ. Anyhow, recombinant IL-2 
has been reported to augment human natural cell-mediated cytotoxicity 
by its own^»16,17. 
The observation that the lytic capacity of SL was induced by IFN-a2 
only after prolonged exposure may suggest that these cells are at a 
different, less mature, stage of differentiation compared to NK cells 
in the peripheral blood. 
In the present study no major differences were observed in the modu­
lation by IFN-a2, IFN-γ and IL-2 of the NK activity displayed by PBL 
and SL between Hodgkin's disease patients and healthy controls. An 
altered responsiveness of NK cells to these cytokines does not appear 
of essential importance in the pathophysiology of HD. 
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SUMMARY 
Splenic lymphocytes (SL) of 21 patients with Hodgkin's disease (HD) 
and 9 controls were characterized for their phenotypes with the use of 
monoclonal antibodies and anti-human immunoglobulin antibodies. SL of 
patients with HD showed a significant increase of T/B lymphocyte ratio 
compared to control SL obtained from accident victims. The increase of 
T/B cell ratio was found in HD spleens independently if involved or 
not. The distribution profiles of helper/inducer and suppressor/cyto-
toxic lymphocytes in previously untreated patients were not different 
whether the splenic tissue was involved by the disease or not. In pre­
viously treated patients a profound decrease was observed in the ratio 
of helper/inducer to suppressor/cytotoxic SL. The increased relative 
number of 0KT10 positive SL might reflect an activated state of a pro­
portion of mature lymphoid cells, expressing T10 antigens. The percen­
tage of lymphocytes which expressed the antigenic phenotype of natural 
killer (NK) and killer (K) cells tended to be higher in HD which might 
be related to augmented cytotoxicity in HD. The described results pro­
vide support for the supposition of a chronic state of immune response 
against a sofar unknown antigenic challenge in unaffected and affected 
spleens of patients with HD. 
INTRODUCTION 
The recent development of specific monoclonal antibodies that distin­
guish cell surface membrane antigens has made it possible to define 
more precisely individual lymphoid subpopulations and their differen­
tiation stage^. 
In Hodgkin's disease (HD) especially Τ cells appear to be involved 
in the pathogenesis, since the immunological deficit in HD represents 
an impairment in Τ lymphocyte function^ and early histologic involve­
ment has been noted in Τ cell dependent areas of lymph nodes, and 
spleens·'»^»^. The number of Τ lymphocytes, determined in single cell 
suspensions or tissue sections of spleens from HD patients, utilizing 
Ε-rosette techniques and anti-T cell monoclonal antibodies have been 
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reported to be either normal^, decreased^ or increased^»^»^»^»'» 
10,11,12,13,14,15. 
Data from literature concerning Τ lymphocyte content and composition 
in spleens with and without histological evidence of disease involve­
ment, are controversial. Equal7>12} decreased^»15 anc| increased 
4,9,10,14,16,17,1В numbers of Τ lymphocytes have been described in HD 
involved spleens in comparison to uninvolved spleens. 
It has been suggested by De Sousa et a l . ^ that sequestration of 
functional Τ cells into lymphoid organs, such as the spleen, might be 
responsible for the observed immune deficiency in HD patients. Although 
isolation of cells from splenic tissue by mechanical and enzymatic 
methods might be subject to errors of sampling, the determination of 
cell surface markers on splenic cells in suspension might identify 
quantitative differences between subpopulations of splenic lymphocytes 
from HD patients and controls. In the present study, we used a panel of 
monoclonal antibodies to characterize lymphoid subpopulations from 
spleens of 21 patients with HD and 9 controls. In addition, membrane 
labeling was performed to assess classification of В cells. 
MATERIALS AND METHODS 
Patients and controls. 
Included in the study were 21 spleens from HD patients, which were 
removed during staging laparotomy for diagnostic reasons or for debulk-
ing, and 9 spleens from subjects who underwent splenectomy because of 
accidental splenic rupture. The clinical staging was performed accord­
ing to the Ann Arbor Staging Classification^O and the Rye nomencla­
ture was used for histopathologic classification21. Five patients had 
been treated previously with a mantle field irradiation alone, or 
mantle field irradiation followed by chemotherapy. The clinical data of 
the patient population are shown in table 1. 
Isolation of splenic lymphocytes. 
After slicing a splenic tissue specimen of about 10 g into small 
pieces, the splenic tissue fragments were gently pressed through a 75 
73 
μιη nylon filter. After incubation for 30 m m at 37°С in Tns-buffered 
Minimum Essential Medium supplemented with 0.05 mg/ml DNAse (deoxynbo-
nuclease I, grade II from bovine pancreas; Boehnnger) and 5% (v/v) 
heat-inactivated pooled human serum the cell suspension was layered on 
a discontinuous Percoli dual density gradient (respectively 1.045 and 
1.077 g/ml) and spun at 800 χ g for 15 min at 20PC. After removing dead 
cells and cell fragments, collecting at the 1.045 interphase, intact 
cells were recovered from the 1.077 interphase and washed once in phos­
phate buffered saline (pH 7.2) supplemented with 1л (v/v) bovine serum 
albumine and 0.1л (v/v) sodium azide (PBS-BSA-NaN3). The cells were re-
suspended in PBS-BSA-NaN3 at a concentration of 4 χ 10^/ml. In 11 HD 
patients and 6 controls a part of the spleen cell suspension was puri­
fied by counterflow centrifugation (CFC), as described previously^, 
and the lymphocytes obtained were assessed simultaneously. 
Antisera. 
Nonfluoresceinated monoclonal antibodies (MoAbs) with well-defined 
specificities were used (Ortho Pharmaceutical Corporation, Rantan, NJ, 
USA): 0KT3 (anti-T3) reacts with all peripheral blood Τ lymphocytes ; 
0KT4 (anti-T4) defines helper/inducer Τ cells and 0KT8 (anti-T8) sup-
pressor/cytotoxic Τ cells; 0KT6 (anti-T6) is restricted to thymocytes 
if lymphoid cells alone are analysed; 0KT9 (anti-T9) recognizes the 
transferrin receptor and is found on proliferating cells of all cell 
lineages; 0KT10 (anti-T10) is found on cells at various stages of dif­
ferentiation of both Τ and В cell and myelomonocytic lineages; 0KM1 
(anti-Mi) detects an antigen on monocytes, granulocytes, and circula­
ting null cells; 0KTa1 (anti-la) recognizes an antigen which represents 
the common frame work region of la in humans and which is present on В 
cells,activated Τ cells and a subpopulation of monocytes and macro­
phages. WTl23 recognizes a Τ lineage specific antigen, which is 
strongly expressed on thymic Τ blasts and peripheral blood Τ cells 
activated by phytohemagglutinin, whereas cortical thymocytes and peri­
pheral blood Τ cells are at varying degrees moderately positive for 
WT1. In addition, two fluoresceine conjugated antibodies (Becton 
Dickinson Monoclonal Center, Inc., Mountain View, CA, USA) were used: 
Leu7, reacting with natural killer (NK)/ killer (K) cells and Leu11a, 
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Table 1. Clinical characteristics of the patient population. 
Stage Histology Patients 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
1Θ 
19 
20 
21 
Age 
18 
17 
24 
24 
45 
57 
31 
62 
18 
47 
31 
36 
57 
34 
22 
41 
20 
29 
19 
35 
19 
Se) 
M 
F 
F 
F 
M 
F 
F 
F 
M 
M 
M 
F 
M 
F 
M 
F 
M 
M 
F 
M 
F 
Spleen involvement Prior therapy 
CSIIA/PSII 
CSIIB/PSII 
CSIIIA/PSIII 
CSIIA/PSII 
CSIA/PSI 
CSIA/PSI 
CSIA/PSI 
CS-B/PSII 
CSIVB/PSIV 
CSIIIA/PSIII 
CSIA/PSIII 
CSIIA/PSII 
CSIIB/PSII 
CSIB/PSIV 
CSIA/PSIV 
CSIIIA/PSIII 
CSIIA/PSIII 
CSIIA/PSII (R) 
CSIIA/PSII 
CSIVB/PSIV (R) 
CSIVB/PSIV (R) 
NS 
NS 
NS 
NS 
LP 
NS 
MC 
LD 
MC 
LP 
NS 
NS 
NS 
MC 
MC 
NS 
LP 
MC 
NS 
MC 
MC 
major 
major 
minor 
minor 
major 
major 
major 
major 
RT 
RT 
RT 
RT+CT 
RT+CT 
CS = clinical stage; PS = pathologie stage; A/B = without/with constitutional symptoms; R = relapse. 
NS = nodular sclerosis; MC = mixed cellularity; LP = lymphocytic predominance; LD = lymphocytic 
depletion. 
RT = radiotherapy (mantle field irradiation); CT = chemotherapy. 
recognizing an antigen present on NK/K cells and granulocytes. The sur­
face membrane immunoglobulins (Smlg) on В cells were identified with 
the use of fluorochrome-conjugated FCab'^ goat anti-human poly­
valent Ig, IgG, IgM, IgA, IgD, kappa and lambda antisera (Kallestad 
Laboratories, Inc., Chaska, MN, USA). 
Flowcytometric analysis. 
After resuspending the cells in PBS-BSA-NaN3 at a concentration of 4 
χ 106/ml, 200 μΐ of the cell suspension was incubated at room tempe­
rature for 30 min with 5 μΐ of the Ortho MoAbs, washed three times and 
subsequently treated for 30 min with 20 μΐ of fluorescein-conjugated 
F(ab,)2 fragment sheep anti-mouse Ig antibodies (Cappel Laboratories, 
Inc., Cochranville, PA, USA). The MoAbs Leu7 and Leulla and the Smlg 
antibodies were also incubated for 30 min at room temperature after the 
addition of 10 μΐ of the antibody to 200 μΐ of the cell suspension. The 
cells were washed three times with PBS-BSA-NaN3 and the final cell pel­
let was resuspended in 600 μΐ of a 1% (v/v) paraformaldehyde solution 
in PBS and stored at 40C for 1 to 7 days until analysis was performed 
on a 50H Cytofluorograph (Ortho Diagnostic Systems Inc., Westwood, MA, 
USA). Green fluorescence, forward and perpendicular light scatter were 
measured at 488 nm in area mode and stored in list mode for analysis by 
a PDP 11/34 computer (Digital Electronic Company, Maynard, MA, USA). 
During analysis of the list mode files, lymphocytes were discriminated 
from monocytes/macrophages and granulocytes on the basis of their cha­
racteristic light scatter properties. Fluorescence signals from cells 
with lymphocyte light-scattering characteristics were recorded to gene­
rate a histogram of cell nunber versus fluorescence intensity, and the 
percentage of cells showing fluorescence was calculated. For each sam­
ple, at least 10.000 cells were analysed. 
5tatistical_analysis. 
Statistical analysis was carried out with the Wilcoxon two sample 
test. The results are expressed as means + SD. 
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RESULTS 
The results of cell surface phenotyping of the splenic lymphocytes 
(SL) from 21 patients with HD and 9 controls are presented in tables 2 
and 3. The proportion ОКТЗ4" lymphocytes in HD patients (61.6 ± 14.9%) 
appeared significantly (p = 0.0002) increased in comparison with con­
trols (32.4 ± 3.9%). No marked difference in percentage of 0KT3+ lym­
phocytes was observed between HD spleens with (63.θ + 16.0%) and with­
out (59.9 ± 14.6л) histological evidence of disease involvement. The 
relative nimber of 0KT3+ SL was not reduced in the 3 patients, who 
underwent staging laparotomy immediately following the completion of 
mantle field irradiation, whereas in 2 with mantle field irradiation 
and chemotherapy heavily pretreated patients the percentage of 0KT3+ 
lymphocytes was low in comparison to the mean percentage of 0KT3+ 
cells of the total patient group. The distribution of 0KT4+ and 
0KT8+ SL expressed as the ratio of 0KT4+ to 0KT8+ lymphocytes was 
comparable in untreated HD patients (range 1.41 - 4.43) and controls 
(range 1.72 - 3.25). However, 0KT4/0KTB ratio was markedly changed in 
all 5 patients, who were treated with radiotherapy or radiotherapy and 
chemotherapy prior to splenectomy (range 0.34 - 0.94). This change in 
0KT4/0KT8 ratio appeared mainly to be due to a reduction in the numbers 
of ΟΙ^"*" lymphocytes but an increase in the number of 0KT8+ lympho­
cytes cannot be excluded. The SL did not demonstrate any reactivity 
with 0KT6. SL from HD patients and controls stained equally with 0KT9 
(8.1 ± 4.7% and 7.1 + 5.1% respectively). The percentage of SL reacting 
with 0KT10 was significantly (p < 0.05) higher in HD (17.4 + 10.2% vs 
9.3 ± 4.4%). No difference was observed between both groups in re­
activity with 0KM1. The number of 0KIa+ cells was significantly (p = 
0.0002) lower in HD (23.4 ± 6.3%) than in controls (48.2 ± 8.4%). The 
MoAbs identifying NK and К cells stained only a minority of the SL and 
the number of positive cells tended to be higher in HD: 11.6 ± 10.2% of 
the SL from HD patients and 4.6 ± 1.5% of the control SL were positive 
for Leu7; a significant difference (p < 0.02) was observed for Leulla, 
8.1 ± 6.1% and 2.8 ± 3.0% respectively. With respect to WTi as well 
in the HD group as in controls approximately 60% of all were positive. 
In table 3 the distribution pattern of surface membrane immunoglobulins 
(Smlg) on В cells are shown. The number of В cell in controls (55.3 ± 
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10.1%) significantly (ρ = 0.0002) exceeded that in HD patients (28.4 ± 
8.8%), as judged from the number of SL positively stained with poly­
valent fluorochrome-conjugated F(ab'^-antibodies (Smlgtot.). The 
distribution of the heavy chain immunoglobulin isotypes of SL resembles 
that of peripheral blood lymphocytes: most В cells residing in the 
spleen bear heavy chain IgM and IgD. In HD apparently more В cells 
simultaneously bear SmlgM and SmlgD in comparison to controls. The 
distribution of ic and λ light chains was similar in spleens from HD 
patients and controls and the relative expression was identical to 
peripheral blood В lymphocytes. The results of cell surface phenotyping 
performed on SL, purified by CFC, were virtually identical and are 
therefore not presented. 
DISCUSSION 
A panel of monoclonal antibodies and conventional antisera have been 
employed to investigate lymphocyte subpopulations in single cell sus­
pensions of HD spleens, and the findings were compared with those ob­
tained in a group of normal control spleens. Our data clearly indi­
cate a significant rise of Τ lymphocytes and a diminution of В lympho­
cytes in HD spleens in comparison to controls. Although no marked dif­
ference in the number of Τ cells was observed between HD patients with 
and without disease involvement of the spleen, the 4 untreated patients 
with heavy splenic involvement displayed the highest number of 0KT-3 
positive splenic lymphocytes (SL). These findings, which are in agree­
ment with data published by others^,14 might point to either an 
obvious antigenic challenge of the neoplastic cell component of the HD 
lesion towards environing SL, or a persistent non-specific immune res­
ponse. In support of the latter hypothesis are the observations of 
elevated serum immunoglobulin levels by Wegener et al.24 and the 
occurence of circulating immune complexes, as reported by Amlot et 
al.25 and Brown et al. 26. in contrast with earlier reports^»^, 
in our series no marked increase in SL with the helper/inducer pheno-
type was observed. Lymphocytes reacting with anti-T4 antibody are, as 
shown by Poppema et al.^ in tissue sections, mainly localized in 
nodular HD lesions, surrounding Reed Sternberg cells. Since we did not 
80 
process exclusively nodular HD lesions, this might explain why our 
results are in this respect at variance with others. With regard to the 
MoAbs 0KT9 and 0KT10, which recognize antigens on immature or activated 
lymphoid cells, but which are both not restricted to cells from 
lymphoid lineage, the higher number of 0KT10+ lymphocytes in HD splenic 
tissue may reflect an activated state of a proportion of mature lym­
phoid cells expressing T10 antigen, rather than the presence of enhanc­
ed numbers of immature lymphocytes since no reactivity with 0KT6 was 
observed. Furthermore, as the percentage of the SL positively staining 
with 0KT9 and WT1 were virtually the same in HD patients and controls, 
the raised number of cells expressing T10 antigen may reflect the 
immunologic activation of a particular subset of SL, whose identity 
remains to be clarified. Since la antigens are expressed on В cells and 
activated Τ cells it is not possible to draw any conclusions on a re­
lative increase or decrease of la-positive Τ lymphocyte subpopulations, 
while in this study the SL were not subfractionated into Τ and В 
cells. The relative increase of lymphocytes positively staining with 
SmIgD in HD patients apparently reflects an increased number of В lym­
phocytes bearing simultaneously SmIgM and SmIgD. This, together with a 
small though definite raised number of SmlgA bearing В lymphocytes in 
HD displayed over controls, possibly is in concurrence with a more pro­
nounced, persistent stimulation of В lymphocytes. This presumption is 
corroborated by the report of Wagener et al.23, who found increased 
serum levels of immunoglobulins in untreated HD patients and by the 
observation of augmented splenic IgG production reported by Longmire et 
al.27. Although expression of surface markers is not absolutely in 
mutual alignment with function, the marginally enhanced nimber of lym­
phocytes reacting with Leu7 and the significantly enhanced number of 
lymphocytes reacting with Leulla, is in concurrence with the enhanced 
NK capability of SL, reported previously28, 
Finally, the finding of a reduced ratio of helper/inducer to suppres-
sor/cytotoxic SL after mantlefield irradiation followed by chemotherapy 
is in concordance with alterations in peripheral blood lymphocyte popu­
lations, described by Posner et al.29. 
81 
REFERENCES 
1. Reinherz EL, Schlossman SF. The differentiation and function of 
human Τ lymphocytes. Cell 19: Θ21-827, 1980. 
2. Engleman EC, Benike CJ, Hoppe RT, Kaplan HS, Berberich FR. Autolo­
gous mixed lymphocyte reaction in patients with Hodgkin's disease: 
evidence for a Τ cell defect. J Clin Invest 66: 149-158, 1980. 
3. Lukes RJ. Criteria for involvement of lymph nodes, bone marrow, 
spleen and liver in Hodgkin's disease. Cancer Res 31: 1755-1767, 
1971. 
4. Pinkus GS, Barbuto D, Said JW, Churchill WH. Lymphocyte subpopula­
tions of lymph nodes and spleens in Hodgkin's disease. Cancer 42: 
1270-1279, 1978. 
5. Poppema S, Bahn AK, Reinherz EL, Posner MR, Schlossman SF. In situ 
immunologie characterization of cellular constituents in lymph 
nodes and spleens involved by Hodgkin's disease. Blood 59: 226-232, 
1982. 
6. Payne SV, Jones DB, Haegert DG, Smith JL, Wright DH. Τ and В lym­
phocytes and Reed-Sternberg cells in Hodgkin's disease lymph nodes 
and spleens. Clin Exp Immunol 24: 280-286, 1976. 
7. Dorreen MS, Habeshaw JA, Wrighley PFM, Lister ТА. Distribution of 
Τ lymphocyte subsets in Hodgkin's disease characterized by mono­
clonal antibodies. Br J Cancer 45: 491-499, 1982. 
8. Kaur J, Catovsky D, Spiers ADS, Galton DAG. Increase of Τ lympho­
cytes in the spleen in Hodgkin's disease. Lancet ii: 800-802, 1974. 
9. Hunter CP, Pinkus G, Woodward L, Moloney WC, Churchill WH. Increas­
ed Τ lymphocytes and IgMEA-receptor lymphocytes in Hodgkin's 
disease spleens. Cell Immunology 31: 193-198, 1977. 
10. Berenyi E, Sonkoly I, Paloczi K, Balzacs GY, Szegedi GY. Τ and В 
lymphocytes in lymph nodes and spleens of patients with Hodgkin's 
disease. Neoplasma 26: 307-313, 1979. 
11. Gupta S, Tan С Subpopulations of human Τ lymphocytes. Clin Immunol 
Immunopath 15: 133-143, 1980. 
12. Possner MD, Reinherz EL, Breard J, Nadler LM, Rosenthal DS, 
Schlossman SF. Lymphoid subpopulations of peripheral blood and 
spleen in untreated Hodgkin's disease. Cancer 48: 1170-1176, 1981. 
13. Herrmann F, Sieber G, Jauer В, Lockner A, Komischke В, Rühl H. Eva-
luation of the circulating and splenic subpopulations in patients 
with Non-Hodgkin lymphomas and Hodgkin's disease using monoclonal 
antibodies. Blut 47: 41-51, 1983. 
14. Romagnani S, Del Prete GF, Maggi E, Bosi A, Bernardi F, Ponticelli 
Ρ, Di Lollo S, Ricci M. Displacement of Τ lymphocytes with the 
"helper/inducer" phenotype from peripheral blood to lymphoid organs 
in untreated patients with Hodgkin's disease. Scand J Haematol 31: 
305-314, 1983. 
15. Stathopoulos G, Papamichail M, Peckham MJ, Davies AJS, Holborow EJ. 
The Τ and В lymphocyte content of lymph nodes and spleen in Hodg­
kin's disease. Br J Exp Pathol 58: 712-716, 1977. 
16. Santoro A, Caillou В, Belpomme D. Τ and В lymphocytes and monocytes 
in the spleen in Hodgkin's disease: the increase in Τ lymphocytes 
in involved spleens. Eur J Cancer 13: 355-359, 1977. 
17. Han T, Minowada J, Subramanian V, Barcos M, Kim U. Splenic Τ and В 
lymphocytes and their mitogenic response in untreated Hodgkin's 
disease. Cancer 45: 467-774, 1980. 
18. Baroni CD, Ruco L, Uccini S, Foschi A, Occhionero M, Marcorelli E. 
Tissue T-lymphocytes in untreated Hodgkin's disease. Cancer 50: 
259-268, 1982. 
19. De Sousa M. In: The immunopathology of lymphoreticular neoplasms. 
Twomey JJ, Good RA (eds.). Plenum, New York, pp 325-359, 1978. 
20. Carbone PP, Kaplan HS, Musshoff К, Smithers DW, Tubiana M. Report 
of the committee on Hodgkin's disease staging classification. 
Cancer Res 31: 1860-1861, 1977. 
21. Lukes RJ, Craver LF, Hall TC, Rappaport H, Rubin P. Report of the 
nomenclature committee. Cancer Res 26: 1311, 1966. 
22. Janssen JThP, De Pauw BE, Smeulders JBJM, Wessels JMC, Haanen C. 
Lymphocyte isolation from human spleen by counterflow centrifuga-
tion employing two different flow chambers on line. J Immunol 
Methods 70: 23-30, 1984. 
23. Tax WJM, Tidman N, Janossy G, Trejdosiewicz L, Willems R, Leeuwen­
berg J, De Witte TJM, Capel PJA, Koene RAP. Monoclonal antibody 
(WT1) directed against a Τ cell surface glycoprotein: characteris­
tics and immunosuppressive activity. Clin Exp Immunol 55: 427-436, 
1984. 
83 
24. Wagener DJTh, Van Munster PJJ, Haanen C. The immunoglobulins in 
Hodgkin's disease. Eur J Cancer 12: 683-6ΘΘ, 1976. 
25. Amlot PL, Prussell B, Slaney JM, Williams BD. Correlation between 
immune complexes and prognostic factors in Hodgkin's disease. Clin 
Exp Immunol 31: 166-175, 1978. 
26. Brown CA, Hall CL, Long JC, Carey K, Weitzmann SA, Aisenberg AC. 
Circulating immune complexes in Hodgkin's disease. Am J Med 64: 
289-294, 1978. 
27. Longmire RL, McMillan R, Yelenosky R, Armstrong S, Lang JE, Crad-
dock CG. In vitro splenic IgG synthesis in Hodgkin's disease. N 
Engl J Med 289: 763-767, 1973. 
28. Janssen JThP, De Pauw BE, Smeulders JBJM, Wessels JMC, Wagener 
DJTh, Haanen C. Natural killer cell activity of lymphocytes from 
spleen and peripheral blood of patients with Hodgkin's disease. 
Submitted for publication. 
29. Posner MR, Reinherz E, Lane H, Mauch Ρ, Hellman S, Schlossmann SF. 
Circulating lymphocyte populations in Hodgkin's disease after 
mantle and paraaortic irradiation. Blood 61: 705-708, 1983. 
84 
CHAPTER 7 
ALTERATIONS IN INTRACELLULAR ENZYME ACTIVITY OF SPLENIC AND PERIPHERAL 
BLOOD LYMPHOCYTES IN HODGKIN'S DISEASE 
J.Th.P. Janssen, P.H.M, de Mulder*, H. van Rennes*, D.J.Th. Wagener*, 
В.E. de Pauw and С. Haanen 
* Department of Medical Oncology 
Submitted for publication in: Human Lymphocyte Differentiation. 
SUMMARY 
Three key enzymes of the carbohydrate metabolism: glucose-6-phosphate 
dehydrogenase (G-6-PDH), phosphohexose isomerase (PHI), isocitrate de-
hydrogenase (ICDH), and two acid hydrolases (N-acetyl-ß-glucosamidase 
(NAG) and acid phosphatase (ACP), were studied in purified peripheral 
blood lymphocytes and splenic lymphocytes of patients with Hodgkin's 
disease (HD). Cell isolation was performed with cell scatter monitored 
counterflow centrifugation. The enzymes were measured in the cell 
lysates by means of fluorimetrie microassays. In peripheral blood lym-
phocytes as well as in splenic lymphocytes from HD patients a signi-
ficantly (p < 0.01) enhanced G-6-PDH and PHI activity was observed 
indicating an increased activity of the hexose monophosphate shunt 
(HMPS) and the glycolytic pathway. The Krebs cycle enzyme (ICDH) showed 
no significantly different value from normal controls. Both lysosomal 
enzymes were significantly (p < 0.01) enhanced in splenic lymphocytes, 
whereas in peripheral blood lymphocytes a clearly, though not signifi-
cantly augmented activity of NAG and ACP was observed. Enzyme activi-
ties in the splenic lymphocytes were at a lower level in comparison 
with peripheral blood lymphocytes. These results provide support for an 
increased metabolic activity of splenic and peripheral blood lympho-
cytes in HD. 
INTRODUCTION 
Although numerous studies both in vivo and in vitro have demonstrated 
the existence of an association between Hodgkin's disease (HD) and im-
paired cell-mediated immunity^'2»3, several of the phenomena asso-
ciated with HD are also in agreement with increased lymphocyte activ-
ity*»5. In HD immune stimulation apparently induces both an increased 
spontaneous proliferation, exhibited by large transformed lymphocytes, 
and simultaneously a depressed ability of other lymphocytes to react to 
new antigenic or mitogenic stimuli. It has been postulated that se-
questration of functional lymphocyte subpopulations in lymphoid organs 
such as the spleen, might account for immune deficiency in patients 
with HD6. 
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Since it may be assumed that functional changes will be a reflection 
of alterations in the underlying metabolic patterns, we measured the 
activity of five key enzymes in splenic and peripheral blood lymphocyt-
es of HD patients and compared the results with those obtained in nor-
mal controls. Both splenic and peripheral blood lymphocytes were iso-
lated with the use of cell-scatter monitored counterflow centrifuga-
tion. The enzymes were assayed by means of microfluorimetric techni-
ques. The following enzymes were studied: glucose-6-phosphate dehydro-
genase (G-6-PDH) of the hexose monophosphate shunt (HMPS), phosphohex-
ose isomerase (PHI) of the glycolytic pathway, isocitrate dehydrogenase 
(ICDH) of the Krebs cycle and two lysosomal enzymes N-acetyl-ß-glucosa-
midase (NAG) and acid phosphatase (ACP). 
MATERIALS AND METHODS 
Patients and controls. 
Peripheral blood lymphocytes of θ newly diagnosed patients with biop­
sy-proven Hodgkin's disease (HD) and of 1 patient with a relapse after 
radiotherapy and chemotherapy were studied and compared with 11 healthy 
controls. Splenic lymphocytes were obtained from 11 spleens of patients 
Table 1. Clinical data of the patient group in which enzyme activity of 
peripheral blood lymphocytes was determined. 
No Age Sex Stage Histology 
LP 
NS 
MC 
NS 
MC 
MC 
(R) NS 
MC 
NS 
CS = clinical stage; А/В = without/with constitutional symptoms; 
R = relapse; NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
35 
29 
46 
47 
28 
26 
35 
13 
74 
M 
M 
M 
M 
M 
M 
M 
M 
M 
CS IV в 
CS IV в 
CS III A 
CS II в 
CS IV А 
CS I A 
CS III A 
CS IV в 
CS IV в 
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with HD and from 6 control spleens of individuals with accidental sple­
nic rupture. The Rye nomenclature was used for histopathologic classi-
fication? and the Ann Arbor Classification for Clinical Staging^. 
The clinical data of both patient groups are listed in tables 1 and 2. 
Table 2. Clinical data of the patient group in which enzyme activity of 
splenic lymphocytes was determined. 
No 
1 
2 
3 
*4 
5 
6 
7 
θ 
9 
•10 
11 
Age 
1B 
17 
24 
20 
24 
45 
57 
31 
62 
18 
20 
Sex 
M 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
Stage 
II 
II 
III 
III 
II 
I 
I 
I 
II 
IV 
II (R) 
Histology 
NS 
NS 
NS 
LP 
NS 
LP 
NS 
NS 
LD 
MC 
MC 
* treated with mantle field irradiation prior to staging laparotomy. 
R = relapse. 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
Lymphocyte isolation. 
Lymphocytes were isolated from peripheral blood and spleens as des­
cribed previously9»1û with the use of cell scatter monitored counter-
flow centrifugation (elutriation). This method permits collection of 
approximately 90% of all elutriated peripheral blood lymphocytes with 
an average purity of 995«. Of all splenic lymphocytes recovered after 
elutriation 88.855 are collected with a purity of > 9855. 
Biochemical assays. 
Enzyme measurements were performed with a fluorimetrie microassay as 
described previously^. The three intracellular enzymes of inter-
mediary metabolism, G-6-PDH, PHI and ICDH were measured by fluorimetrie 
determination of NADPH generated from NADP in the presence of appro-
priate substrates using either direct or coupled systems. The acid hy-
drolases, NAG and ACP, were assayed by fluorimetrie determination of 
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4-methylLimbelliferone released from linked derivatives. After thawing 
of the samples, they were subjected to 2 χ 10 sec ultrasonication at 
(f С and after centrifugation twenty μΐ of the lysate was incubated in 
duplicate with the appropriate substrates and fluorescense determined. 
Activity was expressed in nmol/min^g DNA. 
The DNA content of the lysate was measured by fluorescence of the 
complex with the fluorochrome V6-diamidino-2-phenylindole-2-HCLl2 
using a modification described by Mier et al.13. 
Statistics. 
The Wilcoxon two-sample test was used to evaluate the results, which 
are expressed as means ± standard deviation. 
RESULTS 
The mean purities of peripheral blood lymphocytes for the HD group 
and normal controls were 97 ± 3.7% and 99 ± 0.6% respectively. For the 
splenic lymphocytes the purity was identical in both groups (98 ± 15«). 
In Figs 1 and 2 the results of the enzyme measurements are presented. 
Peripheral blood lymphocytes of HD patients displayed in comparison 
with normal controls a significantly increased G-6-PDH (0.67 ± 0.13 
versus 0.45 ± 0.1 nmol/min.pq DNA; ρ < 0.001) and PHI (5.1 ± 1.1 versus 
3.9 ± 0.7 nmol/min^g DNA; ρ < 0.01) activity. ICDH and the lysosomal 
enzymes NAG and ACP in HD peripheral blood lymphocytes tended to be 
higher, but did not reach a statistically significant difference. Lower 
levels of activity were observed for each enzyme in splenic lymphocytes 
compared to peripheral blood lymphocytes. Intracellular enzyme activity 
in splenic lymphocytes was significantly higher in HD patients compared 
to normals for G-6-PDH (0.33 ± 0.08 versus 0.22 ± 0.03; ρ < 0.01), PHI 
(4.07 ± 2.18 versus 2.18 ± 0.25; ρ < 0.01), ACP (0.028 ± 0.08 versus 
0.013 ± 0.002; ρ < 0.01) and NAG (0.079 + 0.017 versus 0.041 ± 0.006 
пгтюі/тіп.цд DNA; ρ < 0.01). Although ICDH tended to be higher in HD 
splenic lymphocytes, the difference with control splenic lymphocytes 
was not at a statistically significant level (0.15 ± 0.07 versus 0.10 ± 
0.02 nmol/min^g DNA). 
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Fig. 1. Activity of G-6-PDH, PHI, ICDH, ACP and NAG in peripheral blood 
lymphocytes from controls (N) and patients with Hodgkin's disease (HD). 
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F i g . 2. A c t i v i t y of G-6-PDH, PHI, ICDH, ACP and NAG in splenic 
lymphocytes from c o n t r o l s (N) and pat ients wi th Hodgkin's disease (HD). 
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DISCUSSION 
In HD various lymphocyte functions have been described to be either 
enhanced or diminished. The increment of intracellular G-6-PDH activity 
in highly purified splenic and peripheral blood lymphocytes reflects an 
enhanced hexose monophosphate shunt (HMPS) activity, which pathway is a 
major source of cellular NADPH and ribose-5-phosphate, required in DNA, 
RNA and protein synthesis. The increased PHI level in the HD lymphocyte 
populations points to an activation of glycolysis when compared to the 
control groups. Since both enzymes, G-6-PDH and PHI, are supposed to be 
involved in PHA-induced lymphoblastic transformation14»15f our data 
provide support for an increased lymphocyte activity in HD. The Krebs 
cycle enzyme ICDH tended to be higher in HD lymphocytes, but the dif-
ferences did not reach a statistically significant level. 
Although these findings of increased lymphocyte activity in HD are 
apparently in agreement with the observations of increased spontaneous 
lymphocyte transformation in patients with HD, it does not exclude un-
balanced cellular immunoregulatory interactions, resulting in impair-
ment of some immunologic functions. Simultaneously two lysosomal hydro-
lases, NAG and ACP, were assayed. These enzymes which are assumed to be 
involved in cell-mediated immune response, participate in the hydro-
lytic degradation of glycoproteins, mucopolysaccharides and glyco-
lipids. Splenic lymphocytes from HD patients displayed a significantly 
enhanced level of both lysosomal enzymes, whereas the activities in HD 
peripheral blood lymphocytes tended to be increased without reaching a 
statistically significant difference. As already reported for NAG by 
Robinson and Stirling^, the average activity of both hydrolases in 
splenic lymphocytes is markedly decreased in comparison with peripheral 
blood lymphocytes. Studying the lysosomal enzyme ß-glucoronidase in 
peripheral blood lymphocytes from HD patients, Woesner^ found values 
within or above the normal range. In other lymphoproliferative diseases 
the activity of several lymphocytic lysosomal enzymes are shown to be 
either increased^,19
 or decreased^O. Our results are in concordance 
with the assumption of an increased metabolic state of lymphocytes from 
peripheral blood as well as from spleens in HD. The average activity of 
all five enzymes were at a lower level for splenic lymphocytes in com-
parison to peripheral blood lymphocytes, indicating a lower metabolic 
state of lymphocytes residing in the spleen. 
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SUMMARY 
To evaluate purine metabolism in splenic lymphocytes in Hodgkin's 
disease (HD) we studied 3 purine interconversion enzymes: adenosine 
deaminase (ADA), purine nucleoside Phosphorylase (PNP) and purine-51 
nucleotidase (5'NT). These enzymes were measured in purified splenic 
lymphocyte suspensions of 10 patients with HD and 6 normal controls. 
The splenic lymphocytes were isolated with cell scatter monitored coun-
terflow centrifugation. Enzyme activities were measured in the cell 
lysates by means of a radiochemical method. In the splenic lymphocytes 
of HD patients a significantly higher ADA activity (p < 0.01), and a 
lower S'NT activity (p < 0.01) were found compared to control splenic 
lymphocytes. PNP activity was similar in HD and control splenic lympho­
cytes. The alterations in ADA and 5'NT activities might reflect a dis­
turbed maturation of Τ lymphocytes in HD, which might represent a new 
aspect of the immune defect associated with HD. 
INTRODUCTION 
In the past decade, several studies have been performed that demon­
strate an association between certain immunodeficiency diseases and 
imbalances of purine metabolism in lymphocyte subpopulations. Giblett 
et al.1 were the first to report absence of ADA activity in red cell 
lysates of two unrelated girls who exhibited a dysfunction of Τ and В 
cells, clinically manifested by recurrent infections and delayed hyper­
sensitivity reactions. In vitro mitogenic stimulation in these patients 
was impaired and plasma levels of IgG and IgM were low. After the first 
report on ADA deficiency in relation with severe combined immunodefi­
ciency the involvement of purine interconversion enzyme defects in im­
pairment of the immune system has been confirmed 2,3, 
In Hodgkin's disease (HD) various cell-mediated immunological func­
tions are impaired, of which the immunological deficit in Τ lymphocytes 
is the most extensively documented^»5,6,7, To our knowledge no stu­
dies on adenosine deaminase (ADA), purine nucleoside Phosphorylase 
(PNP) and purine-5' nucleotidase (S'NT) in splenic lymphocytes from pa­
tients with HD have been published. 
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Müller^ studied ADA activities in peripheral blood Τ lymphocytes 
from HD patients and observed values approximately three times lower 
than in Τ lymphocytes from healthy control persons. This finding was 
presumed to indicate a disturbed purine metabolism, which might be re­
lated to the dysfunction of Τ cells in HD. In the present study we ana­
lysed ADA, PNP and S'NT activities in highly purified splenic lympho­
cytes from patients with HD and healthy controls. 
Table 1. Patient population. 
No Age Sex PS Histology 
M II NS 
F II NS 
F III NS 
M III LP 
M I LP 
F I NS 
F I MC 
F II LD 
M IV MC 
M II (R) MC 
* treated with mantle field irradiation prior to staging laparotomy. 
R = relapse; M = male; F = female; PS = pathologic stage. 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
MATERIALS AND METHODS 
Patients and controls. 
The individuals studied included ten patients with biopsy-proven HD, 
whose spleens were removed during staging laparotomy. Six healthy sub­
jects, who were splenectomized because of accidental splenic rupture 
were used as a control group. Staging procedures were carried out ac­
cording to the Ann Arbor Clinical Staging Classification^. The histo­
logical material was classified according to Lukes et al.10. Table 1 
summarizes some general characteristics of the ten patients with HD. 
1 
2 
3 
*4 
5 
6 
7 
θ 
9 
*10 
1Θ 
17 
24 
20 
45 
57 
31 
62 
18 
20 
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Lymphocyte isolation. 
Lymphocytes were isolated from human spleen by counterflow centrifu-
gation (elutriation) employing two different flow chambers connected on 
line in one rotor, as reported previously^. Briefly, after the pre­
paration of a single cell suspension the spleen cells were layered on a 
discontinuous Percoli dual density gradient (1.045 and 1.077 g/ml res­
pectively) and spun at 800 χ g for 15 min at 20PC. After removing dead 
cells and cell fragments at the 1.045 interphase, intact cells were 
collected from the 1.077 interphase. Subsequently the cell suspension 
was introduced into the elutriator rotor (Beekman J2-21 С centrifuge 
equipped with a JE-6 elutriator rotor with a combination of the stan­
dard Beekman and the Sanderson chamber on line). Gradually diminishing 
of centrifugal speed at a constant counterflow rate of 12 ml/min per­
mitted cells to emerge from the separation chambers. Optimal purifica­
tion of lymphocytes was achieved by means of continuous cell scatter 
monitoring of the effluent. This method enables collection of 88.8 ± 
1.4Й of all elutriated splenic lymphocytes with a purity of > 98%. 
Enzyme assays. 
Splenic lymphocyte suspensions containing 4 χ 10 cells/ml were pre­
pared in Minimum Essential Medium (MEM, pH 7.35). Aliquots of 25 μΐ 
were frozen at -7CPC for 30 minutes and subsequently lyophilized over­
night. 
The activities of adenosine deaminase (ADA; E.C. 3.5.4.4), purine 
nucleoside Phosphorylase (PNP; E.C. 2.4.2.1) and purine-5'nucleotidase 
(S'NT; E.C. 3.1.3.5) were assayed by a slightly modified radiochemical 
micromethod, described previously^. 
ADA was assayed by measuring the conversion of C-adenosine to C-
14 
inosine. The incubation mixture consisted of 0.30 mM 8- C-adenosine 
(Radiochemical Centre Amersham (RCA), spec. act. 58 mCi/mmol), 0.17M 
Tris (pH 7.4, Merck) and 0.3% (v/v) Triton X-100 (Sigma). 
PNP was assayed by measuring the conversion of C-hypoxanthine to 
C-inosine. The incubation mixture consisted of 0.13 mM 8- C-hypox­
anthine (RCA, spec. act. 55 mCi/mmol), 0.16 M Tris (pH 7,0), 1.6 mM 
ribose-1-phosphate (Boehringer), 32 mM EDTA (Merck) and 0.3S (v/v) Tri­
ton X-100. 
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5'NT was assayed by measuring the conversion of C-AMP to C-adeno-
sine. The incubation mixture consisted of 0.56 mM -^С-АМР (RCA, 
spec. act. 56 mCi/mmol), 0.072 M Tris (pH 8.5), 29 mM МдСІг (Merck), 6 
mM ß-glycerophosphate (Sigma) and 0,3Só (v/v) Triton X-100. 
The enzyme reactions were started by addition of 60 μΐ of an appro­
priate incubation mixture to the lyophilized cells. All enzyme assays 
were carried out in triplicate at 37°C. 
After incubation, separation of substrate and products was performed 
by means of thin-layer chromatography on PEI-cellulose plates (Mache-
rey-Nagel, CEL 300 PEI). Unlabelled metabolites were co-chromatographed 
and after detection under UV light (254 nm) the spots were cut out and 
counted in a liquid scintillation counter (Packard, Tricarb В 2450). 
The chromatography of the PNP and 5'NT reaction mixtures was performed 
using 0,15 M NaCl (Merck) as the solvent. Analysis of the ADA reaction 
mixture was carried out with: tert-butanol (Merck); ethylmethylketone 
(Merck); ammonia (33?ó (v/v), Merck); water (20:15:5:10) as the solvent. 
Identification of Τ and В cells. 
Since differences in the composition of the splenic lymphocyte sus­
pensions might account for differences in activity of the purine inter-
conversion enzymes, the number of Τ cells was identified by means of 
the monoclonal antibody ОКТЗ^ and В cells by membrane fluorescence, 
employing fluorochrome conjugated polyvalent goat anti-human immunoglo­
bulin (Kallestad Laboratories Inc., Chaska, MN, USA). 
Statistics. 
The Wilcoxon two-sample test was used to evaluate the results, which 
are expressed as means ± standard deviation. 
RESULTS 
After elutriation the mean purity of the splenic lymphocytes was 
similar for the HD group and normal controls (> 91%). From all elu-
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triated lymphocytes 84.θ + 3.2Х and 85.9 ± 4.Ой were recovered in the 
patient and the control group respectively. 
Table 2. Percentage of Τ and В cells in the splenic lymphocyte suspen­
sions. 
Patients 
No % Τ cells (0KT3) % В cells (Smlg) 
1 53 20 
2 56 27 
3 44 30 
4 70 20 
5 70 23 
6 69 31 
7 67 26 
8 79 16 
9 87 14 
10 83 9 
Mean 67.8 21.6 
± SD ± 13.6 ± 7.2 
Controls 
No S5 Τ cells (0KT3) % В cells (Smlg) 
1 32 66 
2 35 48 
3 28 61 
4 30 55 
5 23 65 
6 30 55 
Mean 29.7 58.3 
± SD ± 4.0 ±6.9 
In table 2 the data on the distribution of Τ and В cells in the sple­
nic lymphocyte suspensions of the patients and the control persons are 
presented. The mean percentage of Τ cells (67.8 ± 13.6%) in the prepa­
rations from HD patients considerably far exceeded the mean value in 
the control group (29.7 ± 4.05») whereas the percentage of В cells was 
much lower in HD (21.6 ± 7.2SÍ) compared to control (58.3 ± 6.9%) 
spleens. The results of the enzyme measurements are depicted in Fig. 
1. The mean ADA activity of the splenic lymphocytes from patients with 
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HD (130 ± 77 χ 10"9 moles/106 lymphocytes.hour) was significantly 
higher (ρ < 0.01) than the ADA activity in normal control splenic lym­
phocytes (49 ± 10). No significant difference was found in PNP activity 
(170 ± 45 χ 10-9 moles/IO^ lymphocytes.hour in HD patients and 157 
± 27 in controls). In the splenic lymphocytes of HD patients 5'NT acti­
vity was significantly lower: 14 + 9 χ 10~' moles/10^ lympho­
cytes.hour in HD patients and 41 ± 22 for controls (p < 0.01). 
p<0 01 
Fig. 1. ADA, PNP and 5'NT a c t i v i t i e s ( Ю - 9 moles/106 cel ls .hour) in 
splenic lymphocytes from controls (N) and pat ients with Hodgkin's dis­
ease (HD). 
DISCUSSION 
The activities of the purine interconversion enzymes ADA, PNP and 
5'NT were determined in splenic lymphocytes from HD patients and con­
trols. ADA activity was significantly higher in HD splenic lymphocyt­
es. Since no significant differences in the ADA activity have been ob­
served between normal mature Τ and В peripheral blood lymphocytes 
14,15
 anc
j especially immature Τ cells have been reported to exhibit 
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high levels of ADA^,17 the higher ADA activity in the HD splenic 
lymphocytes may be explained by abnormal proportions of mature and im­
mature lymphocytes. 
The significantly lower activity of 5'NT in HD splenic lymphocytes 
provides further support for this hypothesis, for S'NT activity usually 
is found to be low in immature Т-1утрЬосуіез16,18# j^ e acquisition of 
greater plasma membrane 5'NT activity may be one of many Τ lymphocyte 
surface modifications occurring during cell differentiation^. The 
observed differences in ADA and 5'NT activity between HD and control 
splenic lymphocytes therefore rather reflect an increased proportion of 
immature lymphocytes in HD splenic tissue than that it might be ex­
plained by the markedly different distribution of Τ and В cells in the 
HD and control splenic lymphocyte suspensions. 
It might be feasible that a disturbed Τ lymphocyte maturation contri­
butes to the impairment of cellular immunity in HD, as is observed in 
splenic^O as well as in peripheral blood*»5»6,7 lymphocytes. 
PNP enzyme activities were demonstrated to be not significantly dif­
ferent between peripheral blood Τ and В lymphocytes^. Since PNP le­
vels of the total splenic lymphocyte population were similar for both 
groups, HD splenic lymphocytes may be assumed not to be different for 
PNP activity in comparison to control splenic lymphocytes. 
In conclusion, our findings indicating an increased ADA activity and 
a reduced 5'NT activity of HD splenic lymphocytes possibly reflect a 
disturbed maturation of Τ lymphocytes residing in the spleen. This 
might represent a new aspect of the immune defect associated with HD. 
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CHAPTER 9 
DETERMINATION OF NUCLEOTIDE CONTENT IN SPLENIC LYMPHOCYTES FROM 
PATIENTS WITH HODGKIN'S DISEASE AND CONTROLS 
J.Th.P. Janssen, J.M. van Baal*, G. Vierwinden and R.A. De Abreu* 
•Department of Pediatrics 
SUMMARY 
The cellular concentrations of adenosine, guanosine, cytadine and 
undine triphosphate (ATP, GTP, CTP and UTP) were measured in splenic 
lymphocytes from patients with Hodgkin's disease (HD) and controls. 
Splenic lymphocytes were isolated with the use of counterflow centnfu-
gation. The concentrations of ATP, GTP and UTP tended to be higher in 
the splenic lymphocytes from HD patients, although no significant dif-
ferent levels were reached in comparison to controls. The difference in 
CTP concentrations was much less pronounced. Whether this enhancement 
should be ascribed to metabolic differences of the whole splenic lym-
phocyte population or to some subpopulations remains to be clarified. 
INTRODUCTION 
Purine and pynmidine metabolites are essential for human cells: they 
play an important role in the transfer of chemical energy for metabolic 
processes, in DNA and RNA synthesis, in cell proliferation and cell re-
gulation. Pools of ribonucleotides and deoxynbonucleotides were re-
ported to be disturbed in lymphocytes of patients with adenosine deami-
nase deficiency associated with severe combined immunodeficiency 
>f¿tJ, and in lymphoblasts of children with non-T non-B acute lym-
phoblastic leukemia*. In Hodgkin's disease (HD) Aleksijevic et al.5 
described alterations in cyclic nucleotide concentrations of monocyte-
depleted peripheral blood lymphocytes, consisting of significantly de-
creased intracellular concentrations of cyclic monophosphates of adeno-
sine (cAMP) and guanosine (cGMP). This might represent a new aspect of 
the immune defect associated with HD, since cAMP and cGMP are presumed 
to play an important role in the modulation of lymphocyte functions, 
like e.g. natural killer cell-mediated lysis, and in the induction of 
lymphocyte differentiation. 
Like the lymph nodes, the spleen must be considered as an immunologi-
cal organ with the capability of generating a typical humoral immune 
response with development of antibody-producing cells or a cellular 
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immune response with appearance of sensitized lymphocytes after anti-
genic stimulation. Apart from the well-established impaired cellular 
immunity^»?, several of the phenomena associated with HD are suggest-
ive of increased lymphocyte activityö»^ with early lymphoid reactivi-
ty in lymph nodes and spleens without recognizable tumor involvement. 
In order to investigate whether alterations in purine and pyrimidine 
metabolism might be related to the above mentioned phenomena in HD, we 
measured ribonucleotide concentrations in splenic lymphocytes of HD pa-
tients and we compared the results with those obtained in controls. 
MATERIALS AND METHODS 
Patients and controls. 
Splenic lymphocytes were obtained from 11 spleens of patients with HD 
and from 6 control spleens of subjects, who underwent splenectomy be-
cause of accidental splenic rupture. Histological classification and 
staging were performed according to the Rye nomenclature and the Ann 
Arbor recommendations^»^^. The clinical data of the patients are 
presented in table 1. 
Table 1. Clinical data of the patient group, in which nucleotide con-
tent of splenic lymphocytes was determined. 
No Age Sex Stage Histology 
M II NS 
F II NS 
F III NS 
M III LP 
F II NS 
M I LP 
F I NS 
F I NS 
F II LD 
M IV MC 
M II (R) MC 
* treated with mantle field irradiation prior to staging laparotomy. 
R = relapse. 
NS = nodular sclerosis; MC = mixed cellularity; 
LP = lymphocytic predominance; LD = lymphocytic depletion. 
1 
2 
3 
*4 
5 
6 
7 
θ 
9 
10 
11 
1Θ 
17 
24 
20 
24 
45 
57 
31 
62 
1Θ 
20 
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Isolation of splenic lymphocytes. 
The isolation of lymphocytes from spleen was performed with the use 
of cell scatter monitored^ counterflow centnfugation (elutnation), 
as described previously!3. This method permits collection of approx­
imately 88л of all elutriated splenic lymphocytes with an average pu­
rity of 9ВЙ. 
Measurement of nucleotide concentrations. 
The concentrations of nucleotides in the splenic lymphocytes were de­
termined as described previously^. Briefly, nucleotides were extract­
ed from 8 χ 10 6 lymphocytes with ice-cold 0.4 M perchloric acid for 15 
min. Proteins were precipitated by centnfugation and the supernatant 
was adjusted to pH 6.0 - 6.5 with an ice-cold mixture of 0.4 M potas­
sium hydroxide and 1 M dipotassium hydrogenphosphate. Nucleotide con­
centrations weie measured by high-performance liquid chromatography. 
The analyses were carried out using a Spectra Physics SP 8000Θ liquid 
Chromatograph equipped with a two-channel data system. UV detection was 
performed at 254 and 280 nm. Separation was assessed on a pre-packed 
partisil-10 SAX column (250 χ 4.6 mm I.D., particle size 10 μπι: What­
man, Maidstone, UK). 
Statistics. 
The Wi lcoxon two-sample t e s t was used t o e v a l u a t e t h e r e s u l t s , which 
are g i v e n as means ± s t a n d a r d d e v i a t i o n . 
RESULTS 
The purity of the splenic lymphocytes was identical in the patient 
and the control group (9855 ± 1.0). In Fig 1 the results from nucleotide 
concentration measurement are presented. The mean concentration of ATP 
in splenic lymphocytes from HD patients (230 ± 149 pmol/10 cells) 
tended to be higher than from controls (122 ± 21 pmol/10 cells). The 
same tendency was observed for GTP and UTP: for GTP the corresponding 
values were 50 ± 26 pmol/106 cells in HD and 27 ± 6 pmol/10 cells in 
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controls and UTP 33 ± 19 versus 16 ± 4 pmol/10 cells respectively. Al­
though the concentrations of ATP, GTP and UTP tended to be higher in 
splenic lymphocytes from HD patients, the differences were not statis­
tically significant. The concentrations of CTP were almost identical in 
both groups: 9.4 ± 6 in HD versus 9.2 ± 3 pmol/106 cells in controls. 
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Fig. 1. Concentrations (pmol/106 cells) of UTP, CTP, ATP and GTP in 
splenic lymphocytes from controls (Ν) and patients with Hodgkin's dis­
ease (HD). 
DISCUSSION 
Although the mean concentrations of the 4 ribonucleotides measured in 
HD patients were not significantly different from controls, in at least 
half of the patients the values for ATP, GTP and UTP exceeded the high­
est control values. This might point to a higher metabolic state in 
these patients, which is in support of an increased lymphocyte activity 
in HD. Like in malignant lymphoblasts from children with non-T-non-B-
ALL the increase in CTP is much less pronounced. 
Since we analyzed the splenic lymphocyte population as a whole, it is 
unclear whether the increase of ribonucleotide concentrations is pre-
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sent in all lymphocytes or is limited to certain subpopulations. When 
limited e.g. to the suppressor cell subpopulation, it might contribute 
to the impaired cellular immunity, or when limited to immunoreactive 
cells, it might just reflect the enhanced state of the immune system. 
Due to the very small numbers of patients, it is impossible to relate 
the data to stage of disease or histological subtypes. The clinical re­
levance remains to be clarified, since it might be an aspecific pheno­
menon as has been found for other phenomena in HD. 
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SUMMARY 
Twelve patients with advanced lymphoproliferative diseases were 
treated intramuscularly with recombinant interferon-alpha 2 in a 
three-daily escalating dose. The most common side effects were flu-like 
symptoms. Two patients showed severe neurotoxicity, which was complete­
ly reversible in one case. Doses above 30 million units per day were 
poorly tolerated and could only be achieved in one patient. Objective 
tumor responses were documented in 6 patients: one with Hodgkin's dis­
ease, two non-Hodgkin lymphoma and three hairy cell leukemia patients. 
INTRODUCTION 
Interferons are a family of glycoproteins with distinctive biological 
properties, of which the ability to impair virus replication is the 
most prominent^>2. Furthermore, they interfere with the immune system 
at several levels'. Early clinical trials, employing buffy coat-de­
rived leukocyte interferon, have shown activity against lymphoprolife­
rative diseases, multiple myeloma, malignant melanoma, renal cell car­
cinoma and Kaposi's sarcoma *»5>6
φ
 jh
e u s e 0f recombinant DNA techni­
ques has facilitated the production of interferon, offering a consider­
able reduction of costs and improved purity. 
This study was designed to assess the tolerance and pharmacokinetics 
of intramuscularly administrated human interferon-alpha 2. Concomitant­
ly the antitumor activity was evaluated. 
MATERIALS AND METHODS 
Patients. 
Twelve patients with Hodgkin's disease, non-Hodgkin lymphoma or hairy 
cell leukemia, of each four, entered this study. All patients, except 
two patients with hairy cell leukemia, were treated with chemotherapy 
and radiotherapy prior to their inclusion. 
The ages ranged from 20 to 63 years. The mean Karnofsky performance 
status was 65, ranging from 30 to 100. Patients were evaluated prior to 
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treatment with complete history, physical examination, measurement of 
hemoglobin, white blood cell count with differentiation, number of pla­
telets, serum electrolytes, creatinine, calcium, blood glucose, uric 
acid, transaminases, bilirubin, LDH, CPK, serumimmunoelectrophoresis 
and urine-analysis. Bone marrow examination, electrocardiogram, chest 
X-ray and other Х-гауз or scans, as required to define the extent of 
the disease, were also performed before start of treatment. 
During the first 14 days blood pressure, pulse rate, respiration fre­
quency, and body temperature were recorded daily before and 2, 6, and 
10 hours after administration of interferon. Thereafter these parame­
ters were registered weekly. 
Human recombinant interferon-alpha_2-arg (IFNa2). 
IFNa2 was obtained from Boehringer-Ingelheim International, D-6507 
Ingelheim am Rhein, FRG. The degree of purity exceeded 9в%. The speci­
fic activity was 3.2 χ 10 units/mg protein. 
IFNa2 was administered daily, after obtaining informed consent, by 
the intramuscular route in an escalating dose of 5-10 million units 
every 3 days, up to the maximum tolerated dose. After establishing the 
maximum tolerated dose, several patients were treated for longer pe­
riods with individually adapted dosages. 
IFNa2-serum levels. 
Serun levels of IFNa2 were measured by means of a radioimmunoassay. 
Serum samples were taken on the first day of therapy and on days of 
dosage escalation before and 2, 6, 10 and 24 hours after administra­
tion. 
anti-IFNa2 antibodies. 
Blood for antibody testing against IFNa2 was drawn before, after 8 
weeks of therapy, and at the termination of treatment. 
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Table 1. Patient population and individual therapy. 
Number Diagnosis 
1. Hodgkin's disease 
2. Hodgkin's disease 
3. Hodgkin's disease 
4. Hodgkin's disease 
5. Non-Hodgkin lymphoma 
(diffuse centrocytic-
centroblastic) 
6. Non-Hodgkin lymphoma 
(immunoblastic) 
7. Non-Hodgkin lymphoma 
(follicular centrocyt 
centroblastic) 
8. Non-Hodgkin's lymphom 
(immunoblastic) 
9. Hairy cell leukemia 
10. Hairy cell leukemia 
11. Hairy cell leukemia 
12. Hairy cell leukemia 
M = male 
F = female 
+ = s t i l l on treatment 
RESULTS 
The clinical characteristics of the patients, including age, sex, un­
derlying disease, maximum tolerated dosage, and duration of therapy are 
summarized in Table 1. The maximal dose of IFNa2 administered was 40 χ 
ΙΟ** units/day which was tolerated by only one patient for 2 weeks. 
The dose-limiting toxicity consisted of a complex of side effects, such 
as fever, fatigue, loss of appetite, nausea, and chills, as summarized 
in table 2. Fever appeared 2-6 hours after administration and was most­
ly limited to the first 3 weeks of treatment. In almost all pabients a 
decrease of the leukocyte count was noted. In 4 patients the leukocyte 
count dropped below 2000/ml, constituting an obstacle for dosage in­
crease. Thrombocytopenia (< 100.000/ml) existed in 6 patients. In the 6 
other patients with normal pretreatment platelet levels, thrombocyto­
penia developed in one patient which necessitated a dose reduction of 
ic-
a 
age 
37 
30 
20 
31 
42 
3Θ 
sex 
M 
F 
F 
M 
M 
M 
Max 
toi 
im um 
erated 
dose 
(x 10bUni 
30 
20 
20 
30 
20 
25 
ts/day) 
Duration 
of therapy 
(days) 
240 
42 
15 
43 
21 
18 
50 M 40 135 
36 
54 
51 
63 
52 
M 
M 
M 
M 
M 
30 
25 
30 
30 
30 
138 
265+ 
56 
24 
175+ 
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IFNaZ. In 1 patient a rise in serum creatinine was observed; this, how-
ever, was associated with the prefinal stage of the patient. In some 
patients a slight increase of the transaminase levels was registered 
which was compatible with continuation of the study drug. 
Antitumor responses were encountered in one patient with Hodgkin's 
disease, whose pulmonary lesions decreased to 15Ä of the initial size 
during 18 weeks of treatment with a daily dose of 10 χ 10^ units 
IFNa2. Regrowth, however, was seen after switching to a maintenance 
dosage of 10 χ 10^ units 3 times a week. In two patients with a 
malignant non-Hodgkin lymphoma (cases 7 and 8), a decrease of the size 
of the lymph nodes of more than 50л was observed, which lasted for 16 
weeks in both cases. The following responses were observed in patients 
with hairy cell leukemia: one patient with a severe pancytopenia and a 
pulmonary infection of fungal origin showed a minimal increase of the 
neutrophil count in the peripheral blood during 2 months of treatment 
with 20 χ 10^ units/day. In 2 patients a normalization of the peri­
pheral blood values was registered, accompanied by a more than 50% re­
duction of the hairy cell infiltration in the bone marrow. One patient 
showed a complete remission of 3 months short lasting duration. 
Therapy had to be discontinued for various reasons. In one patient 
IFNccZ therapy was withdrawn temporarily because of the development of a 
Wernicke-Korsakoff syndrome and signs of Parkinsonism. He was subse­
quently demonstrated to suffer from a thiamin deficiency. In a second 
patient a neuralgic amyotrophy and polyradiculopathy developed which 
improved only slowly after discontinuation of IFNo2 therapy. The thera­
py was ultimately withdrawn in 9 patients because of lack of response 
or timor progression. 
Table 2. Incidence 
Fatigue 
Fever 
Loss of appetite 
Nausea 
Dizziness 
Headache 
Myalgia 
Mental changes 
Neurotoxicity 
Chills 
Vomitus 
Impotence 
Loss of hair 
of moderate and severe side effects. 
83S 
75% 
61% 
lil% 
33% 
33% 
25% 
M% 
25% 
17Ä 
17% 
25% 
17Ä 
No patient showed detectable serum IFNa2 activity prior to treat­
ment. In spite of the administration of identical dosages variable 
levels of serum IFNa2 activity were detected in individual patients at 
given points. Generally, peak levels were measured 2-10 hours after 
i.m. injection of IFNa2. The peak serum concentrations varied consider­
ably among patients. At a dosage of 20 χ 10^ units/day, seгил levels 
ranged from 72 to 400 units/ml with a mean of 202 units/ml. Antibodies 
to interferon were not found in any patient. 
DISCUSSION 
Interferons have been given in a variety of doses, routes and sche­
dules. The experience with daily administration of high doses, however, 
is limited. The results of this study show that recombinant IFNa2 ad­
ministered daily in escalating trial doses, is associated with toxic 
effects comparable to those observed with other dose regimens^»8, y(-,
e 
major dose-limiting factor appeared to be a flu-like syndrome consist­
ing of fatigue, fever, chills, anorexia, myalgia, headache, and mental 
changes. Fever seemed to be related to the peak levels of IFNa2, which 
were achieved in the peripheral blood. This may indicate that the toxic 
reactions are inherent to the interferon molecule itself. The occur­
rence of similar effects during treatment with non-recombinant inter­
feron seems to corroborate this supposition'. Fever and chills were 
usually limited to the first weeks of therapy, whereas the other symp­
toms, notably fatigue, tended to persist. 
Thrombocytopenia and leukocytopenia were seen in a minority of the 
patients and necessitated dose reduction in one patient. Using dosages 
up to 40 χ 10^ units of IFNa2, only mild disturbances of the liver 
function were noted. 
Apart from the commonly observed signs of neurotoxicity^» ^ , ma­
nifested by somnolence, lethargy, and decreased ability to perform the 
daily activities, we registered two severe cases of neuropathy. One pa­
tient, who was shown to be thiamin deficient, developed a Wernicke-Kor­
sakoff syndrome and signs of Parkinsonism, which disappeared with thia­
min substition and temporary withdrawal of IFNa2, and the second pa­
tient acquired a neuralgic amyotrophy combined with worsening of a pre-
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existent polyneuropathy, which occurred within a few days. After dis­
continuation of IFNtxZ in the latter patient an improvement, but not 
complete recovery was seen. These observations urge vigilance in all 
patients on interferon treatment and early withdrawal of the agent in 
cases where Polyneuropathie symptoms develop. Impotence and loss of 
hair were less prominent, albeit complaints of inconvenience. 
Although considerable individual variation existed, the severity of 
side effects mentioned above seemed to be dose-related. Almost all side 
effects appeared to be reversible after dose reduction or discontinua­
tion of IFNa2. 
This study also documents objective evidence of antitumor activity of 
recombinant IFNa2 in patients with malignant lymphomas and hairy cell 
leukemias confirming the data from literature^. 
In contrast to previous studies*, no antibodies against IFNa2 were 
detected, employing a daily administration scheme. This could be due to 
the particular purity of the IFNci2 preparation or the consequence of 
the limited nunber of patients, who have been exposed to IFNa2 for 
longer periods of time during this study. 
REFERENCES 
1. Paucker K, Cantell K, Henle W. Quantitative studies on viral inter­
ference in suspended L cells: III. Effect of interfering viruses 
and interferon in the growth rate of cells. Virology 17: 324-334, 
1962. 
2. UCLA Conference. Interferon: Immunobiology and clinical signifi­
cance. Ann. Int. Med. 96: 80-93, 19Θ2. 
3. Krim К. Towards tumor therapy with interferons. Part I. Interfe­
rons: production and properties. Blood 55: 711-721, 1980. 
4. Foon FA, Sherwin SA, Abrams PG et al. Treatment of advanced non-
Hodgkin lymphoma with recombinant leukocyte A interferon. 
N.Engl.J.Med. 311:1148-1152, 1984. 
5. Quesada JR, Hawkins M, Horning S et al. Collaborative phase I-II 
study of recombinant DNA-produced leukocyte interferon (clone A) in 
metastatic breast cancer, malignant lymphoma, and multiple myeloma. 
Am.J.Med. 77: 427-432, 1984. 
119 
6. Krown SE, Real FX, Cunningham-Rundles S. Preliminary observations 
on the effect of recombinant leukocyte A interferon in homosexual 
men with Kaposi's sarcoma. N.Engl.J.Med. 308: 1071-1076, 1983. 
7. Shah I, Band J, Samson M et al. Pharmacokinetics and tolerance of 
intravenous and intramuscular recombinant alpha 2 interferon in pa-
tients with malignancies. Am.J.Hemat. 17: 363-371, 1984. 
8. Gutterman JU, Fine S, Quesada J et al. Recombinant leukocyte A in-
terferon: Pharmacokinetics, single dose tolerance, and biologic 
effects in cancer patients. Ann.Int.Med. 96: 549-556, 1982. 
9. Quesada JR, Rueben J, Manning JT et al. Alpha interferon for in-
duction of remission in hairy cell leukemia. N.Engl.J.Med. 310: 
15-18, 1984. 
10. Mattson K, Niiranen A, livanainen M et al. Neurotoxicity of inter-
feron. Cancer Treatm.Rep. 67: 960-961, 1983. 
11. Sherwin SA, Knost JA, Fein S et al. A multiple-dose phase I trial 
of recombinant leukocyte A interferon in cancer patients. J.Amer. 
Med.Ass. 248: 2461-2466, 1982. 
120 
SUMMARY AND GENERAL CONCLUSIONS 
In chapter 1 a short introduction and an outline of the investiga­
tions are presented. 
In chapter 2 a modified and improved counterflow centrifugation tech­
nique for the isolation of lymphocytes from human spleen is described. 
By combining the standard Beekman and the Sanderson separation chambers 
on line in 1 rotor, the problem of pelleting of cells at the inlet of 
the separation chamber was overcome. 
In chapter 3 the results of antibody-dependent cellular cytotoxicity 
mediated by purified splenic and peripheral blood lymphocytes (Ly-ADCC) 
are presented. The method used is based on the difference in DNA con­
tent between the lymphocyte effector cell and the chicken red blood 
cell (CRBC) target. Analysis was performed by means of DNA flow cytome­
try. A significantly depressed ADCC was found in both splenic and peri­
pheral blood lymphocytes of patients with Hodgkin's disease (HD) com­
pared to controls. The depressed ADCC in vitro suggests a functional 
defect of a lymphocyte subpopulation, which might reflect a relevant 
phenomenon in vivo, contributing to the impaired immunity in HD. Modu­
lation of ADCC by IL-2 was absent in the peripheral blood and splenic 
lymphocytes from some HD patients. This IL-2 unresponsiveness argues 
for a reduced IL-2 receptor density on effector lymphocytes or a defect 
at the level of the IL-2 receptor interaction site in HD patients. 
Chapter 4 outlines the results of natural killer (NK) cell activity, 
which was analysed in peripheral blood lymphocytes and found in HD pa­
tients not to be different from normal controls. When, however, the 
data were examined in relation to the stage of the disease or the pre­
sence of В symptoms, patients with advanced disease or with В symptoms 
demonstrated a significantly decreased NK activity in comparison to 
those with limited disease or without В symptoms. HD splenic lymphocyt­
es displayed an enhanced NK cell activity over control splenic lympho­
cytes. In two cases of HD with massive disease involvement of the 
spleens, the splenic lymphocytes showed an almost complete absence of 
NK capacity. The data may reflect an activation of NK cells early in 
the disease with progressive deterioration of cell-mediated cytotoxic 
functions as Hodgkin's disease progresses. 
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Chapter 5 reports on the in vitro immunomodulatory effects of recom­
binant human interferons (IFN) and interleukin-2 (IL-2) on NK cell 
activity. In general, the ability of NK cells from HD patients to res­
pond in vitro to exogenous IL-2, IFN-a2 and IFN-γ was not different 
from controls. Surprisingly, IFN-γ failed to potentiate NK capacity of 
peripheral blood and splenic lymphocytes from HD patients and controls. 
In chapter 6 the results of cell surface phenotyping are given. In 
agreement with the data from literature the splenic lymphocytes of pa­
tients with HD showed a significant increase of T/B cell ratio compared 
to control splenic lymphocytes. In previously treated patients a pro­
found decrease was observed in the ratio of helper/inducer to suppres-
sor/cytotoxic splenic lymphocytes as a result of radiotherapy or radio­
therapy followed by chemotherapy. 
In chapter 7 the results of intracellular enzyme analyses are report­
ed as measured in splenic and peripheral blood lymphocytes from HD pa­
tients and controls. The enhanced activities of glucose-6-phosphate 
dehydrogenase (G-6-PDH), phosphohexose isomerase (PHI), N-acetyl-ß-
glucosamidase (NAG) and acid phosphatase (ACP) provide support for an 
increased metabolic activity of peripheral blood and splenic lympho-
cytes in HD. 
Analysis of the purine interconversion enzymes adenosine deaminase 
(ADA), purine nucleoside Phosphorylase (PNP) and purine-S' nucleotidase 
(S'NT) in chapter 8 showed a significantly higher ADA activity and a 
significantly lower 5^Т activity in splenic lymphocytes from HD pa­
tients in comparison to control splenic lymphocytes, which might re­
flect a disturbed maturation of splenic Τ lymphocytes in HD. 
In chapter 9 additional support is provided for an increased metabo­
lic activity of splenic lymphocytes from HD patients, since the intra­
cellular concentrations of the ribonucleotides adenosine triphosphate 
(ATP), guanosine triphosphate (GTP) and uridine triphosphate (UTP) in 
HD splenic lymphocytes were, although not significantly, higher in com­
parison to control splenic lymphocytes. 
123 
In chapter 10 some aspects of treatment with IFN-a2 in patients 
with Hodgkin's disease and other lymphoproliferative diseases are des-
cribed. Anti-tumor responses were noted in 1 patient with HD, in 2 pa-
tients with non-Hodgkin lymphoma and in 3 patients with hairy cell leu-
kemia. 
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SAMENVATTING 
De ziekte van Hodgkin, genoemd naar Thomas Hodgkin, die deze aandoe-
ning voor het eerst heeft beschreven in 1832, neemt een aparte plaats 
in onder de kwaadaardige lymfeklieraandoeningen. Opvallend bij deze 
ziekte is de verscheidenheid in architectuur en celsamenstelling van 
het tumorweefsel, waarin cellen, die een rol lijken te spelen bij de 
interactie tussen tumor en gastheer, de overhand hebben. Ondanks een 
ogenschijnlijk verhoogde immunologische reactiviteit ter plaatse van 
het kwaadaardige proces, is gebleken dat bijna altijd sprake is van een 
verlaagde cellulaire immuniteit. Het bestaan hiervan werd voor het 
eerst vermoed door Dorothy Reed in 1902. Zij had opgemerkt, dat bij 
sommige patiënten met de ziekte van Hodgkin na intracutane toediening 
van tuberculine de huidreactie uitbleef. De afgelopen decennia is veel 
onderzoek verricht naar de mogelijke rol van de lymfocyt in dit immuno-
logisch defect, met name naar het bestaan van een defect van de Τ cel 
en naar een toename van suppressor mechanismen. Relatief weinig studies 
hebben betrekking op de eventueel gestoorde bewakingsfunctie van "natu­
ral killer" en "killer" cellen bij het ontstaan van de ziekte van 
Hodgkin. Aangezien één van de belangrijkste aspecten van het immunolo-
gisch bewakingsmechanisme is dat het ontstaan van tumorcellen geasso-
cieerd is met, en in feite wordt voorafgegaan door, een verminderde 
immunologische afweer, lijkt meer uitgebreid onderzoek van natural 
killer activiteit en antilichaam afhankelijke cytotoxiciteit bij de 
ziekte van Hodgkin gewettigd. 
Veel aspecten omtrent de rol van de milt in het immunologisch systeem 
zijn nog onopgehelderd. Het is bekend dat de milt een belangrijk onder-
deel vormt van het mononucleair fagocyterend systeem. Bovendien speelt 
dit orgaan een rol bij de primaire humorale antilichaam respons. In de 
milt van patiënten met de ziekte van Hodgkin wordt meestal een toename 
van het aantal Τ lymfocyten gezien, onafhankelijk van het feit of het 
orgaan door de ziekte is aangetast of niet. Over de betekenis hiervan 
bestaat nog geen eenduidige mening. Van spontaan proliferende lymfo­
cyten bij de ziekte van Hodgkin is beschreven, dat sequestratie in de 
milt plaatsvindt. In hoeverre dit ook gebeurt met cytotoxische lymfo­
cyten en over de eventuele betekenis hiervan is niets bekend. 
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In hoofdstuk 1 wordt na een korte inleiding een beknopt overzicht ge-
geven van het doel en werkplan van het onderzoek. 
In hoofdstuk 2 wordt een methode beschreven voor het verkrijgen van 
lymphocyten uit humaan miltweefsel. Na het maken van een celsuspensie 
worden de lymfocyten gescheiden van de andere miltcellen met behulp van 
een Beekman tegenstroom centrifuge, welke is voorzien van een scatter 
bank waarmee de celgrootte van de uitgewassen cellen continu kan worden 
gevolgd. Met de standaardopstelling ontstond zeer frequent een samen-
klontering van cellen op de bodem van de scheidingskamer, waardoor de 
vloeistofstroom werd belemmerd en een goede scheiding onmogelijk werd. 
Door twee typen kamers met een verschillend scheidingsprofiel in serie 
te combineren in één rotor, werd dit probleem voorkomen. Op deze manier 
werden lymfocyten verkregen met een hoge zuiverheid (> 98%), een uit-
stekende viabiliteit (95%) en een goede opbrengst (80,8%). 
Een van de effector functies van lymfocyten is het antilichaam afhan-
kelijke celdodende vermogen (Ly-ADCC). Deze functie werd onderzocht 
voor lymfocyten uit milt en bloed (hoofdstuk 3). Voor het meten van 
deze functie werd gebruik gemaakt van een methode, die gebaseerd is op 
het verschil in DNA gehalte tussen kippe-erythrocyten en lymfocyten. 
Het percentage gelyseerde, met antilichaam gecoate, kippe-erythrocyten 
werd bepaald met behulp van DNA-flowcytometrie. Bij patiënten met de 
ziekte van Hodgkin bleek de Ly-ADCC van lymfocyten zowel uit de milt 
als uit het bloed verlaagd. Dit suggereert een functioneel defect van 
een subpopulatie van lymfocyten. Deze verlaagde, in vitro gemeten, 
Ly-ADCC kan een weerspiegeling zijn van een relevant phenomeen in vivo, 
wat bijdraagt aan de totstandkoming van de verlaagde cellulaire 
immuniteit bij patiënten met de ziekte van Hodgkin. Bij sommige 
patiënten werd de Ly-ADCC niet hoger na toevoeging van interleukin-2 
(IL-2). Dit wijst in de richting van hetzij een verminderde dichtheid 
van IL-2 receptoren op effector lymfocyten of een defect van de IL-2 
receptor bij sommige patiënten met de ziekte van Hodgkin. 
Natural killer (NK) cellen zijn effector cellen, die een spontane cyto-
toxiciteit bezitten tegen verschillende soorten doelwitcellen. In vivo 
spelen zij een rol bij de afweer tegen het ontstaan van kanker en in-
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fectieziekten. Uit de resultaten, die zijn weergegeven in hoofdstuk 4, 
blijkt dat de NK activiteit van lymfocyten uit het bloed van patiënten 
met de ziekte van Hodgkin niet verschilt van normale personen. Wanneer 
echter de gegevens worden geanalyseerd in relatie tot het stadium van 
de ziekte en de aan- of afwezigheid van generalisatie verschijnselen, 
bleek de NK activiteit van patiënten in stadium III/IV of patiënten met 
generalisatie verschijnselen verlaagd in vergelijking met patiënten in 
stadium 1/11 of patiënten zonder generalisatie verschijnselen. De NK 
activiteit van miltlymfocyten afkomstig van patiënten met de ziekte van 
Hodgkin was in vergelijking met lymfocyten van controle personen 
verhoogd. In 2 gevallen, waarin de milt massaal geïnfiltreerd was door 
Hodgkin nodi, was de NK activiteit nagenoeg afwezig. Deze gegevens kun-
nen passen bij een activitatie van NK cellen in de vroege fase van de 
ziekte en een afname van de NK activiteit met het voortschrijden van de 
ziekte. 
De resultaten betreffende de invloed van interferonen en IL-2 op de 
NK activiteit van lymfocyten uit milt en bloed zijn beschreven in 
hoofdstuk 5. Er werd geen verschil gevonden tussen patiënten met de 
ziekte van Hodgkin en normale personen. Gamma interferon bleek geen 
invloed te hebben op de NK activiteit van milt- en bloedlymfocyten van 
zowel patiënten met de ziekte van Hodgkin als van normale personen. 
Het aantal Τ lymfocyten in milten van patiënten met de ziekte van 
Hodgkin is sterk verhoogd in vergelijking met dat van normale perso-
nen. Bij voorheen behandelde patiënten bleek de verhouding tussen de 
miltlymfocyten met het helper fenotype en die met het suppressor feno-
type omgekeerd te zijn in vergelijking met onbehandelde patiënten. Deze 
gegevens die werden verkregen met membraan labelingstechnieken, zijn 
weergegeven in hoofdstuk 6. 
In hoofdstuk 7, θ en 9 zijn de resultaten beschreven van de bestude­
ring van enige metabole aspecten van de lymfocyten. De verhoogde acti­
viteit van de intermediaire enzymen glucose-6-phosphaat dehydrogenase 
(G-6-PDH) en phosphohexose isomerase (PHI) en de zure hydrolasen 
N-acetyl-P-glucosamidase (NAG) en zure fosfatase (ACP) past bij een 
toegenomen metabole activiteit van milt- en bloedlymfocyten bij de 
ziekte van Hodgkin. 
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Het feit dat de intracellulaire concentraties van de ribonucleotiden 
adenosine trifosfaat (ATP), guanosine trifosfaat (GTP) en uridine tri-
fosfaat (DTP) in miltlymfocyten van patiënten met de ziekte van Hodgkin 
verhoogd zijn, vormt hiervoor een extra argument. De verhoogde activi-
teit van het purine interconversie enzym adenosine deaminase (ADA) en 
de verlaagde activiteit van purine-5' nucleotidase (5'NT), gemeten aan 
miltlymfocyten van patiënten met de ziekte van Hodgkin zou kunnen wij-
zen op een gestoorde rijping van T-lymfocyten in de milt van patiënten 
met de ziekte van Hodgkin. 
In hoofdstuk 10 komen enkele klinische aspecten aan de orde van de 
behandeling met alpha interferon van patiënten met de ziekte van 
Hodgkin en enkele andere lymfoprol iferatieve aandoeningen. Als gevolg 
van de behandeling werd een verkleining van de tumor massa gezien in 1 
patiënt met de ziekte van Hodgkin, in 2 patiënten met een non-Hodgkin 
lymfoom en in 3 patiënten met een hairy cell leukemie. 
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De verhoogde activiteit van het enzym adenosine-deaminase en de ver-
laagde activiteit van purine-S'nucleotidase, gemeten aan miltlymfocyten 
van patiënten met de ziekte van Hodgkin, zou kunnen wijzen op een ge-
stoorde rijping van Τ lymfocyten in de milt van patiënten met de ziekte 
van Hodgkin. 
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Bernsen PLJA, Wong-Chung RE, Janssen JThP. 
Neuralgic amyotrophy and polyradiculopathy during 
interferon therapy. Lancet i: 50, 1985 
VI 
In geval van febris e causa ignota bij een neutropenische patiënt, die 
behandeld wordt met cyclosporine, is ceftazidime het antibioticum van 
de eerste keus. 
De Pauw BE, De Witte Th, Janssen RM, Holdrinet RSG. 
Ceftazidim vergrössert nicht die Nephrotoxizität 
von cyclosporin-Α bei febrilen Patienten mit 
Knochenmarks-transplantation. Der Krankenhausarzt 
57: 854-858, 1984 
VII 
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autologe reinfusie, van patiënten met een non-Hodgkin lymfoom van hoge 
maligniteitsgraad vormt een minder groot probleem dan het tumor-
vrijmaken van de patiënt zelf. 
Vili 
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